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ABSTRACT  
In Sweden, 2000 patients are diagnosed with rectal cancer annually. Developments in surgery 
have improved survival and the addition of preoperative radiotherapy (RT) or 
chemoradiotherapy (CRT) has reduced local recurrence rates to 5 %. However, (C)RT is 
associated with side effects. In order to achieve balance between improved outcomes and risk 
of treatment-associated morbidity, optimized treatment selection is crucial. Guidelines for 
rectal cancer management are mainly based on tumour characteristics from magnetic 
resonance imaging (MRI). Thus, correct interpretation of MRI is essential for optimal 
selection. In addition, all pre-therapeutic information available, e.g. on age and comorbidity, 
should ideally be taken into consideration in treatment-decisions. The aim of this thesis was to 
increase the knowledge regarding preoperative treatment selection in rectal cancer. 
Paper I aimed at evaluating the influence of pretherapeutic parameters on preoperative 
treatment selection. Patients undergoing elective abdominal rectal cancer surgery 2000-2010 
in the Stockholm-Gotland region were included (n = 2619). Patients with comorbidity or old 
age (≥ 80 years) received less preoperative (C)RT. Deviations from guideline 
recommendations regarding preoperative (C)RT were revealed. 
From the study cohort of paper I, patients with stage I-III tumours were included in Paper II 
(n = 2300). The influence of age and comorbidity on long-term outcome after preoperative 
(C)RT, was evaluated. Overall, preoperative (C)RT did not influence long-term outcome but 
in patients with comorbidity overall survival was improved following preoperative (C)RT 
whereas no significant differences were seen among the elderly (≥ 80 years). 
The objective of Paper III was to investigate the performance and reporting of rectal cancer 
MRI and the influence on preoperative treatment selection. MRI investigations and reports on 
94 patients were re-evaluated. Predefined standards for rectal cancer MRI were not 
universally applied. Because of incomplete original reports, clinical tumour staging was 
possible in only 70 % of the patients. The agreement was unsatisfactory both regarding 
tumour staging between the re-evaluation and the original reports and regarding treatment 
selected compared to recommended after re-evaluation. 
Paper IV assessed the MRI characteristics of the primary tumour regarding prediction of 
outcomes after surgery for local recurrence. Treatment selection for the primary tumour was 
also evaluated. Patients undergoing surgery for local recurrence 2003-2013 at Karolinska 
University Hospital were included (n = 54). No factors on primary tumour MRI were found to 
predict long-term outcomes after surgery for local recurrence. However, a MRI-detected 
primary tumour response to preoperative (C)RT correlated to fewer R0 resections of the local 
recurrence. Only 11 of 30 patients with locally advanced primary tumour received 
preoperative CRT.  
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BACKGROUND  
Epidemiology 
More than 1.3 million patients worldwide are diagnosed with colorectal cancer annually and it 
is the third most common form of cancer. The colorectal cancer incidence shows a strong 
variation throughout the world with the highest incidence rates in Europe, Northern America, 
Australia and New Zealand and the lowest in Africa, Middle East and Asia. In Australia and 
New Zealand the age-standardised incidence rate is 44.8 for men and 32.2 for women per 
100,000 and in Western Africa 4.5 and 3.8, respectively. Worldwide, there are almost 
700,000 deaths from colorectal cancer every year, equivalent to 8.5 % of the total mortality. 
The difference in mortality rates is less pronounced than that of incidence rates between the 
developed and the less developed regions1. 
Rectal cancer is responsible for one third of all colorectal cancer. In Sweden some 2000 
patients are diagnosed with rectal cancer every year and about 40 % of them are women2. The 
rectal cancer incidence increases by age and in Sweden almost one fourth of all rectal cancer 
patients are at least 80 years old at diagnosis (Figure 1a)3. The incidence of rectal cancer 
increases slowly but the age-standardised rectal cancer incidence has not substantially 
changed the last decades (Figure 1b). In 2015 the age-standardised rectal cancer incidence 
was 25 per 100,000 among men and 15 per 100,000 among women, respectively. The age-
standardised mortality in rectal cancer decreased from the 1970s through the 1990s in Sweden 
but has been relatively stable the last 15 years. For men, the age-standardised mortality rate 
was 10 per 100,000 and for women 7 per 100,000 in 2015 (Figure 1b)4. For patients who were 
diagnosed with rectal cancer in 2005-2009 the relative 5-year survival for men and women 
was 61 % and 64 %, respectively3. 
 
Figure 1. a. Rectal cancer incidence in Sweden according to age group. b. Age-standardised 
rectal cancer incidence and mortality 1980 – 20115.  
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Aetiology 
According to the model described by Vogelstein et al., colorectal adenocarcinoma develops 
from adenomas through sequential mutations of oncogenes and genes that suppress 
tumorigenesis, a process that takes many years6. In a second pathway, mutations in the DNA 
mismatch repair system leads to inactivation of tumour suppressor genes7. Sporadic tumours 
account for about 80 % of all colorectal cancers whereas the remaining 20 % are found in 
patients with a family history of colorectal cancer8. As the incidence of colorectal cancer 
varies throughout the world, it is believed that sporadic colorectal cancers are associated with 
life style factors. A high intake of red meat and fat, a diet with a low proportion of fibre, 
smoking, high alcohol consumption, obesity and diabetes mellitus are related to increased risk 
of colorectal cancer. Other known risk factors for sporadic colorectal cancer are advanced 
age, male sex, a history of colorectal polyps or cancer and inflammatory bowel disease 
(Crohn´s disease and ulcerative colitis), especially with severe grade of inflammation8. 
Patients with a family history of colorectal cancer have a 2 to 4 fold increased risk of having 
colorectal cancer9. Among the 2-5 % of all colorectal cancer patients with defined hereditary 
syndromes such as Lynch syndrome, familial adenomatous polyposis and MUTYH-
associated polyposis, the lifetime risk of developing colorectal cancer are 50-100 %10. 
 
Anatomy 
Rectum is the most distal part of the gastrointestinal tract before the anal canal. Several 
definitions regarding proximal and distal limits of the rectum exist. Surgeons usually consider 
the muscular anorectal ring as the lower border whereas the upper border is considered to be 
the promontory on radiological examination or by surgery. In the European Society for 
Medical Onchology (ESMO) guidelines, rectal tumours are defined as lesions ≤ 15 cm from 
the anal verge with a rigid rectoscope11. The dentate line in the anal canal represents the 
border of the columnar epithelium of the rectum and the stratified squamous epithelium of the 
lower anal canal. The mesorectum within the mesorectal fascia (MRF) is fatty tissue that 
contains arterial blood supply and venous and lymphatic drainage of the rectum. In the upper 
rectum the mesorectum is located dorsally while more distally it is circumferential, enclosing 
the rectum down to the pelvic floor.  
The arterial blood supply of the upper rectum derives from the inferior mesenteric artery that 
continuous into the superior rectal artery. The inferior rectal artery, a branch of the internal 
iliac artery, supplies the lower rectum. Some individuals also have a middle rectal artery 
originating from the internal iliac artery. The venous drainage from rectum runs through rectal 
veins to the internal iliac vein. The lymphatic drains mainly along the superior rectal artery to 
the inferior mesenteric nodes but especially for the lower third of rectum, also along the 
middle rectal artery to the internal iliac artery. Clinically the nodes along the internal iliac 
artery and in the obturator spaces are often referred to as lateral pelvic nodes. From the anal 
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canal below the dentate line lymphatic drainage also occurs to superficial inguinal nodes12.  
 
Besides the rectum the pelvis contains several other organs and vital structures such as the 
iliacal vessels, autonomous nerves innervating anorectal and urogenital tract, somatic nerves, 
urinary bladder, uterus, ovaries, vagina, prostate and seminal vesicles. This, together with the 
narrow space of the pelvis, requires considerable consideration in rectal cancer treatment, 
both regarding planning of surgery and radiation therapy. 
 
Histopathological staging 
After rectal cancer surgery a pathologist should assess the resected specimen macroscopically, 
before the microscopic analysis is undertaken. An examination of the tumour and resection 
surfaces and optimally also a mesorectal grading is performed to evaluate the quality of the 
total mesorectal excision (TME). According to this three-graded classification, the resected 
mesorectum should be judged as complete, nearly complete or incomplete and it has been 
shown to correlate to outcome after rectal cancer surgery13. 
 
TNM 
In order to describe cancer tumours by stage, the Tumour Node Metastasis (TNM) 
classification of malignant tumours was created. The TNM classification enables prognosis 
assessment, treatment selection and evaluation of treatment effect for cancer tumours. The 
TNM classification is developed and revised by the Union for International Cancer Control 
(UICC) and the American Joint Committee on Cancer (AJCC). The 7th edition, recommended 
in the Swedish national guidelines for colorectal cancer, was published in 20093, 14. 
T stage 
In colorectal cancer, the T describes the primary tumour regarding the depth of invasion and if 
there is growth into adjacent organs (Figure 2). The prognosis deteriorates with each stage 
and substage of T15, 16.  
 
 
 
  
 
 
    
 
  Figure 2. T stage colorectal cancer.  
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N stage 
N refers to metastatic involvement of regional lymph nodes. Presence of tumour deposits, i.e. 
mesenteric metastatic nodules near the primary tumour without signs of lymphatic tissue, is 
also included in the N-stage. A higher level of T stage is associated with a increased risk of 
regional lymph node metastases17.  
M stage 
M describes whether metastases in distant organs, non-regional lymph nodes or peritoneal 
carcinomatosis are present or not.   
 
 
Table 1. TNM classification of colorectal cancer, 7th edition14. 
  
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria into the pericolorectal tissues 
T3a Minimal invasion: <1 mm beyond the borders of the muscularis propria 
T3b Slight invasion: 1-5 mm beyond the borders of the muscularis propria 
T3c Moderate invasion: >5-15 mm beyond the borders of the muscularis propria 
T3d Extensive invasion: >15 mm beyond the borders of the muscularis propria 
T4 Tumour penetrates the visceral peritoneum and/or directly invades other organs or structures 
T4a Tumour penetrates to the surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
  
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c Tumour deposit(s) in the subserosa, mesentery or nonperitonealized pericolic or perirectal 
tissues without regional nodal metastasis 
N2 Metastasis in ≥4 regional lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in ≥7 regional lymph nodes 
  
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to one organ or site 
M1b Metastases in more than organ/site or peritoneum 
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The histopathological TNM staging (pTNM) for colorectal cancer is the result of the analysis 
of the resected specimen whereas the clinical TNM staging (cTNM) is based on preoperative 
radiological examination. The prefix y is used for staging after neoadjuvant therapy. Table 1 
shows the colon and rectum cancer staging according to the TNM classification. 
 
Table 2. Colorectal cancer stage according to TNM and Dukes´ classification. 
T N M TNM Stage Dukes 
   
Tis N0 M0 0 - 
   
T1-2 N0 M0 I A 
   
T3 N0 M0 IIA 
B T4a N0 M0 IIB 
T4b N0 M0 IIC 
   
T1-2 N1 M0 / T1 N2a M0 IIIA 
C T3-4a N1 M0 / T2-3 N2a M0 / T1-2 N2b M0 IIIB 
T4a N2a M0 / T3-4a N2b M0 / T4b N1-2 M0 IIIC 
   
Any T Any N M1a IVA 
D 
Any T Any N M1b IVB 
   
 
 
Dukes classified tumours according to primary tumour invasion and regional lymph node 
status already in the thirties and later presence of distant metastasis was added18. However, 
the Dukes´ classification has largely been replaced by the TNM classification in the staging of 
colorectal cancers. In Table 2 colorectal cancer classifications according to TNM and Dukes 
are shown. Figure 3 displays the TNM stage dependent prognosis as reported by the Swedish 
colorectal cancer registry. 
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Figure 3. Relative rectal cancer survival according to TNM stage in Sweden 2008-20152. 
 
Circumferential resection margin (CRM) 
The shortest distance between the lateral border of the rectal tumour or tumour deposit and 
the resection margin is defined as the circumferential resection margin (CRM). Quirke et al. 
established the CRM as a major predictor for local recurrence in rectal cancer in 198619. Since 
then several studies have confirmed the strong association between CRM involvement and 
inferior long-term outcomes, both regarding local and systemic control and survival20. A 
positive CRM (CRM+) is usually defined as a CRM ≤ 1 mm and a negative CRM (CRM-) as 
a CRM > 1 mm. Other limits such as 2 mm have been proposed, although without changing 
practise as the 1 mm limit remains as the gold standard21.  
 
Distal resection margin (DRM) 
Rectal cancer spread occurs not only laterally but also proximally and distally. Traditionally a 
distal resection margin (DRM) of at least 5 cm and later 2 cm has been considered necessary 
to include distal tumour deposits and to optimise local control22. According to a review 
examining the sufficient DRM, distal intramural spread is seen in 25 % of the patients but 
only in 10 % > 1 cm distally of the primary tumour22. The authors concluded that a DRM of 
1-2 cm is sufficient since tumour spread beyond 1 cm is associated with systemic disease and 
in these relatively few patients a wider DRM will not influence long-term outcome. In the 
Swedish national guidelines for colorectal cancer a DRM of at least 1-2 cm is accepted in low 
and middle rectal cancer, given that TME is performed. A 5 cm DRM is motivated in upper 
rectal cancer in patients undergoing partial mesorectal excision (PME)3. 
 
Residual tumour 
Residual tumour (R) describes the microscopic or macroscopic tumour involvement directly 
at the distal or circumferential resection margin and has been incorporated in the TNM 
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classification (Table 3)14. Hence, a CRM positive specimen (≤ 1 mm) could still be defined as 
R0. There have been attempts to unify these two histopathological variables using the 
minimal distance in the CRM definition into a renewed R classification, although so far 
without great impact in reports published23. The presence of residual tumour in the resected 
specimen (R1 or R2) is clearly correlated to inferior survival and increased rates of local 
recurrence and distant metastasis24. 
 
Table 3. Classification of Residual Tumour14. 
RX Residual tumour cannot be assessed 
R0 No residual tumour 
R1 Microscopic residual tumour 
R2 Macroscopic residual tumour 
 
Vascular invasion 
According to the Swedish national colorectal cancer guidelines, type of vascular tumour 
invasion should be specified so that lymphatic invasion is reported as L (0/1), intramural 
venous invasion as V (0/1) and extramural venous invasion as EMVI3. The histopathological 
detection of venous invasion in rectal cancer is associated with a higher risk of distant 
metastasis and worse survival outcomes whereas lymphatic vessel invasion predicts for 
lymph node metastasis25-27. Inconsistencies regarding terminology and variability in 
recognition and diagnosis make results from investigations in this field difficult to compare 
and in a recent review the reported prevalence of EMVI varied between 9 to 61 %28, 29.  
 
Perineural invasion 
Controversies exist concerning the definition of perineural invasion (PNI) in rectal carcinoma. 
PNI was defined by Batsakis in 1985 as tumour growth in, around and through peripheral 
nerves while some other authors have proposed a subdivision in PNI surrounding the nerve 
sheath and PNI invading through the nerve sheath30, 31. Although the definition and thereby 
the diagnosis of PNI is afflicted by discrepancies, it remains as an independent prognostic 
factor32, 33. 
 
Histopathological grading 
The vast majority of colorectal cancers are adenocarcinomas, which originate from the 
epithelial cells of the mucosa of colon and rectum. Mucinous adenocarcinomas (greater than 
50 % mucinous) represent the second most common form of colorectal cancer while signet 
ring cell carcinomas, neuroendocrine carcinomas, adenosquamous carcinomas and medullary 
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carcinomas are more uncommon34. Adenocarcinomas can be graded based on the proportion 
of normal glandular formation into well, moderately and poorly differentiated and the less 
differentiated tumours have poorer survival outcomes35. However, to reduce the interobserver 
variability and increase the prognostic significance, a stratification into two grades has been 
proposed so that well and moderately differentiated tumours are defined as low grade and 
poorly differentiated as high grade36. This two-tier categorisation is recommended in the 
Swedish national guidelines for colorectal cancer3. 
 
Tumour regression 
Tumour regression refers to the effect of neoadjuvant radio- or chemoradiotherapy on the 
tumour. The tumour regression grade (TRG) is determined by the amount of residual tumour 
cells and the extent of fibrosis induced by the neoadjuvant therapy37. A high degree of tumour 
regression is correlated to better survival and lower rates of local recurrence38. Several TRG 
scales have been developed, for example by Mandard and Dworak but there is no consensus 
on which one is the preferable39, 40. Hence, comparison of prognosis and treatment selection in 
different reports is somewhat difficult. In the Swedish national guidelines for colorectal 
cancer treatment the TRG scale as defined by AJCC is recommended (Table 4)41. 
 
Table 4. TRG scale according to AJCC41. 
0 Complete regression, no viable cancer cells 
1 Moderate regression, single cells or small groups of cancer cells 
2 Minimal regression, residual cancer outgrown by fibrosis 
3 Poor regression, extensive residual cancer 
 
Clinical investigation and staging 
Clinical presentation 
Common symptoms of rectal cancer include anaemia, rectal bleeding, rectal pain, change of 
bowel habits, anal incontinence, abdominal pain, weight loss and fatigue. Presentation of 
rectal cancer can also be related to locally advanced tumour growth with urogenital symptoms 
or pain from the pelvis or limbs as a result of the tumour compressing pelvic structures. 
Furthermore, synchronous distant metastasis can give rise to the presenting symptoms and 
under the investigation for other diseases a small number of patients will be diagnosed with 
rectal cancer en passant by radiological examination. Finally, a proportion of patients are 
diagnosed with rectal cancer through screening programs for colorectal cancer including 
faecal tests and/or endoscopy12. 
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Clinical examination 
The symptoms in rectal cancer vary and may commonly also be present for other both benign 
and malign diseases. Therefore there is a certain risk of delay in the diagnosis and the 
threshold for clinical examination should be low. In patients presenting with anaemia and 
rectal bleeding further investigation is mandatory to rule out neoplasms in the colon or 
rectum, especially in patients > 40 years since colorectal cancer incidence increases with age. 
A digital rectal exam should be performed including description of mobility and surface in the 
case of a rectal tumour. The size and the distance of the lower border from the anal verge are 
examined with a rigid rectoscope and biopsies are taken to establish the diagnosis. The 
categorisation of tumour level depending on the distance from anal verge differs between 
guidelines. According to the ESMO guidelines rectal cancers should be classified into low (0-
5 cm), mid (> 5- 10cm) and high (> 10–15 cm)11. To rule out synchronous colon tumours or 
polyps a colonoscopy or a computed tomographic colonography should be undertaken. 
 
Imaging to detect distant metastasis 
About one fifth of patients with colorectal cancer will have synchronous metastases at 
diagnosis, sometimes at multiple locations42. The most common location for synchronous 
distant metastases in colorectal cancer is the liver followed by the lungs, peritoneum and non-
regional lymph nodes while other metastatic locations such as are bones, brain and ovaries 
and more uncommon42.  
 
Computed Tomography (CT) 
To detect systemic disease a CT of the thorax, abdomen and pelvis is included in the work-up 
of rectal cancer. The sensitivity and specificity of CT for hepatic metastasis is relatively good 
while regarding imaging of the lungs, a number of unspecified nodules are found and only in 
about one fourth of these lesions metastases are established43. Historically the sensitivity 
offered by CT in detecting peritoneal metastases has been low. With emerging techniques 
such as the multidetector CT (MDCT) the performance of CT has improved even though 
small lesions and certain anatomical locations remains to be a challenge and the results 
reported regarding sensitivity and specificity vary44. 
 
Magnetic resonance imaging (MRI) 
The specificity of (MRI) is comparable to CT for hepatic metastases of colorectal cancer but 
MRI has a higher sensitivity, especially for smaller lesions 45. In Sweden MRI of the liver is 
mainly used for re-evaluation of lesions difficult to categorize with CT and for surgical and 
oncological planning after a CT has confirmed liver metastasis. 
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Abdominal ultrasonography (AUS) 
Contrast-enhanced AUS of the liver is fairly inexpensive and can be performed with relatively 
good accuracy regarding liver metastases but is not generally recommended because of its 
low sensitivity in patients with fibrosis or steatosis and for the detection of small lesions (< 5 
mm)46. Furthermore some lesions are difficult to assess with AUS because of their position in 
the liver (i.e. subdiafragmatic), and US examination is also highly operator dependent. 
Finally, AUS does not enable planning of the liver surgery in the same way as MRI47. Thus, 
contrast-enhanced AUS is above all an alternative when MRI cannot be performed. 
 
FDG-PET/CT 
In FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) investigations a 
radioactive tracer (i.e. Fluorine 18) is incorporated into a glucose analogue (FDG) and after 
injection into the patient, the positron emission decay of the short-lived radioisotope can be 
detected using the PET scanner48. Because of the increased metabolism in tumour cells, 
glucose (FDG) uptake is higher and therefore tumours can be revealed49. Combining FDG-
PET with contrast enhanced CT allows for the detection of smaller lesions and a more precise 
determination of the tumour location47. FDG-PET/CT can also adequately evaluate tumour 
response to chemotherapy and thereby be of importance in the selection of treatment 
strategy49. On the other hand, the sensitivity of FDG-PET/CT in detecting tumours is reduced 
in patients that have received chemotherapy50. Also, whereas FDG-PET/CT is sensitive in the 
detection of areas with increased metabolic activity it cannot sufficiently differ tumour from 
inflammation or postoperative findings and the sensitivity of the detection of mucinous 
tumours is low49. Furthermore FDG-PET/CT is expensive and does not enhance the 
diagnostic accuracy of hepatic colorectal metastases compared to MRI49. In the Swedish 
national guidelines for colorectal cancer FDG-PET/CT is therefore not recommended as a 
routine investigation in primary rectal cancer but it is considered a valuable tool to rule out 
extra-hepatic distant metastases and to assess the curative options in patients with locally 
advanced or recurrent rectal cancer3. 
 
Imaging for local tumour growth 
Endorectal Ultrasonograpy (EUS) 
EUS is a relatively inexpensive procedure but also operator-dependent and associated with a 
learning curve51. Furthermore, EUS is not possible in patients with stenosing tumours. The 
accuracy of EUS to assess tumour invasion into the rectal wall is relatively good (69-94 %), 
especially for early (T1) and advanced (T3-4) tumours52. However, restaging after 
neoadjuvant treatment is more accurate with MRI and the diagnostic value of EUS in 
detecting lymph node involvement is rather low52, 53. In many centres EUS is therefore used 
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merely as a complement to MRI, especially for early tumours. 
 
Magnetic resonance Imaging (MRI) 
The development of MRI for the pretherapeutic staging of the local tumour growth has had a 
profound effect in rectal cancer management. Correctly performed high resolution T2-
weighted MRI can adequately stage primary rectal cancer and thereby optimize treatment 
selection. Also, MRI enables restaging after neoadjuvant treatment and predicts resectability 
and oncological outcomes54-56. 
T stage 
According to a systematic review and meta-analysis including rectal cancer patients who did 
not receive neoadjuvant therapy and where histopathology was used as the reference standard, 
the sensitivity and specificity for preoperative MRI-based T stage was 87 % (95 % CI 81-92) 
and 75 % (95 % CI 68-80) respectively57. MRI can adequately measure extramural tumour 
growth and differ between substages of T3 tumours thereby predicting the risk of local 
recurrence after surgery16, 58. For the staging of early tumours and distinction between T1/T2 
tumours, MRI accuracy is relatively low and instead EUS is recommended52, 59. 
 
 
Figure 4. T2 weighted magnetic resonance images of the pelvis in a male patient with rectal 
cancer. a. Sagittal view where the semi annular rectal tumour is clearly depicted in its dorsal 
aspect (white arrows). b. Transaxial view showing a mesorectal lymph node (ML), the 
mesorectal fascia (MRF) and a lateral lymph node (LL) in the left obturator fossa. 
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N stage 
Brown et al. showed that MRI can predict mesorectal lymph node involvement based on 
irregular contour and mixed signal intensity with a sensitivity of 85 % (95 % CI 74-92) and a 
specificity of 97 % (95 % CI 95-99)60. In this study the lymph node size, measured as the 
short-axis diameter, was an inaccurate predictor of metastatic growth. Although it appears as 
if there is an association between nodal size and the risk of metastatic growth the optimal cut 
off seems to be difficult to find whereas a low cut off will render a high sensitivity but a low 
specificity while a high cut off will lead to low sensitivity and a high specificity61. Despite the 
promising results from Brown et al. the morphological criteria have not been universally 
adopted, possibly because small nodes are difficult to evaluate. In a meta-analysis MRI 
performance was more disappointing regarding sensitivity (range 54-76 %) and specificity 
(range 59-87 %) for lymph node involvement62. Restaging of suspected mesorectal nodes 
after neoadjuvant chemotherapy however appears to be more adequate with accuracy ranging 
between 64 - 88 %63. Historically the presence of mesorectal lymph node metastases has been 
associated with increased rates of local recurrence but with TME surgery, N status appears to 
be of less importance as a predictor of local control64. 
Lateral lymph nodes 
The data on incidence and relevance of lateral lymph node metastases in rectal cancer is 
relatively sparse. According to a Japanese multicentre trial that randomised 701 patients with 
stage II-III low rectal cancer to TME surgery alone or TME and lateral lymph node dissection 
(LLND), the proportion of patients with lateral lymph node metastases in the latter group was 
7 %65. Another retrospective Japanese study including patients with low (< 8 cm) T3/T4 rectal 
cancer, reported metastatic lateral lymph nodes in 17 % of the patients66. In a study by Kim et 
al. the presence of positive lateral lymph nodes based on lymph node short-axis diameter of ≥ 
5 mm on pre-treatment MRI, predicted for a lateral local recurrence (26.6 % vs. 2.3 %, p < 
0.001) in patients with primary rectal cancer who underwent preoperative radiochemotherapy 
but not LLND67. The MERCURY study group showed that the disease-free survival (DFS) 
was inferior in primary rectal cancer patients with positive lateral lymph nodes on 
pretherapeutic MRI compared to in patients without suspicious lateral lymph node 
involvement (42 % vs. 70.7 %, p < 0.001)68. However, in this retrospective investigation 
lateral lymph node involvement were defined by the presence of irregular capsular border or 
mixed signal intensity and not by size. 
Mesorectal fascia (MRF) 
CRM is a strong prognostic indicator in rectal cancer surgery19, 20. MRI can accurately 
identify the MRF that represents the surgical circumferential resection plane when TME 
surgery is performed and thereby foresee the surgeon’s possibility to accomplish a clear 
CRM69. The MERCURY study group reported an accuracy of 87 % of MRI-based CRM 
compared to histopathology70. In multivariate analyses an involved CRM according to MRI 
was statistically significantly associated with inferior rates of overall survival (OS), DFS and 
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local recurrence. In another recently reported German prospective multicentre study with T4 
rectal cancer, MRI accurately predicted a negative histopathological CRM in 98.3 % of the 
patients71. 
Extramural venous invasion (EMVI) 
MRI before and after neoadjuvant therapy can adequately identify the presence of EMVI 
(mrEMVI) in rectal cancer72, 73. Several investigations have reported mrEMVI to be highly 
specific (88-96 %) when correlated to histopathology while the sensitivity (28-62 %) appears 
to be lower72, 74, 75. Nevertheless, mrEMVI is a strong predictor for survival and distant 
spread, both before and after preoperative chemoradiotherapy (CRT)72-74, 76. 
Preoperative treatment response 
The evaluation of preoperative treatment response with MRI in rectal cancer is an area of 
increasing attention, both regarding prediction of outcomes and complete response, but 
conclusive data and clinical implications so far is limited77. The MERCURY study showed 
that TRG can be assessed with MRI (mrTRG) after preoperative (chemo-)radiotherapy 
((C)RT) by using differences in signal intensity between tumourous and fibrous tissue in the 
rectal tumour78. In this investigation, the 5-year OS was 27 % vs. 72 % (p = 0.001) and the 5-
year DFS 31 % vs. 64 % (p = 0.007) for a good compared to a poor mrTRG. The predictive 
role of a good mrTRG has also been shown for low rectal cancers79. Also, Nougaret et al. 
reported that volumetric assessment with MRI in patients receiving preoperative CRT is of 
prognostic significance80. In this study a tumour volume reduction of at least 70 % was 
correlated to a better DFS (HR 13.7; 95 % CI 3.98-31.93). 
Locally advanced and locally recurrent tumours 
Imaging of locally advanced primary rectal cancer and locally recurrent rectal cancer is 
demanding regarding diagnosis, staging, prediction of resectability and outcomes81. MRI for 
local recurrence lacks specificity in the differentiation between tumour regrowth and fibrotic 
scar tissue but the use of diffusion-weighted MRI appears to be promising in this respect82, 83. 
While locally advanced primary rectal cancer is staged by the same criteria as non-advanced 
primary rectal cancer, several classifications of local recurrence based on anatomical 
localisation in the pelvis exist that give predictive information regarding resectability and 
prognosis81. In the widely adopted classification from the Memorial Sloan Kettering group the 
pelvis is separated in 4 compartments: Axial, anterior, posterior and lateral84. Several 
investigations using preoperative MRI for locally recurrent rectal cancer have shown that an 
axial recurrence compared to a posterior or lateral recurrence has superior outcomes regarding 
R0 resection rate and OS, after curatively intended surgery85-87. 
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Multidisciplinary team (MDT) conference 
 
When all information from the pretherapeutic investigation is collected, a decision on 
treatment selection should be made. Since there are many therapeutic options and strategies 
including radiation, chemotherapy and surgery for primary tumour and metastases, several 
competences must be gathered for the optimal decision-making. Improved staging and 
increased knowledge of predictive indicators enables more individualised rectal cancer 
management but also makes treatment selection more complex. In the last decades MDT 
conferences have been introduced as a routine in cancer care, but also in the management of 
other diseases.  
In rectal cancer the MDT usually includes colorectal surgeons, oncologists, radiologists, 
pathologists and a specialised nurse but the composition varies depending on specific needs 
and local routines. Each patient can be discussed at several MDT conferences: after staging 
but before preoperative treatment, after preoperative treatment and after surgery but also 
throughout the care of metastases or local recurrence. Treatment recommendations are made 
based on pre- or postoperative stage but must also be made with individual patient factors 
such as age and comorbidity in mind. The final treatment decisions, however, should always 
be made together with the patient. The use of MDT conference has increased continuously 
and in Sweden 97 % of all rectal cancer patients are now discussed at an MDT conference 
before undergoing surgery2. 
The use of MDTs as a routine practise in rectal cancer care has evolved without the support of 
strong evidence. There is a lack of randomised studies in this area and this will probably not 
change since it is believed that MDT conferences is beneficiary for the patients and the 
omittance of MDT discussions in a randomised trial would be unethical. However, there are 
reports supporting the benefit of MDT conferences in rectal cancer management such as 
increased usage of pretherapeutic MRI, more complete staging, increased use of neoadjuvant 
treatment, increased proportion of CRM negative and R0 resections, decreased postoperative 
mortality and improved local control88-91. It appears that MDT conferences, although resource 
demanding, are not associated with any other disadvantages. 
Staging and treatment decisions at the MDT-conferences are aided by national and 
international guidelines. However, the organisations issuing these guidelines such as the 
European Society of Medical Oncology (ESMO), the European Rectal Cancer Consensus 
Conference (EURECCA-CC2) and the National Comprehensive Cancer Network (NCCN) 
differ in their recommendations regarding some of the aspects of rectal cancer management11, 
92-94. Furthermore, guidelines usually do not take patient characteristics such as age and 
comorbidity into account. 
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Swedish Colorectal Cancer Registry (SCRCR) 
 
The Swedish Rectal Cancer Registry was initiated in 1995 and the Swedish Colon Cancer 
Registry in 2007 and the two separate registries have since then merged into the SCRCR 
administered by the regional cancer centres (RCC) in Sweden. Reporting from surgeons, 
oncologists and pathologists to the register include information on pre- and postoperative 
staging, surgery performed, postoperative course, neoadjuvant and adjuvant therapy, 
palliative treatment, treatment of metastases, recurrence and follow-up. All data are registered 
prospectively. Information on death is also available through linkage to the Swedish Cause of 
Death Register administered by the Swedish National Board of Health and Welfare. Data on 
comorbidity is not included in the SCRCR. 
The SCRCR is continuously revised and annual reports from the registry allows for the 
comparison of rectal cancer management between hospitals and regions in Sweden. The high 
coverage (> 99 %) and data validity in the SCRCR make it a valuable source of information 
for population-based investigations95, 96. 
 
The Swedish National Patient Register 
 
This register is maintained by the National Board of Health and Welfare, a Swedish 
government agency. Registration started in the 1960s and became mandatory in 1984. Since 
1987 it includes information regarding in-patient care from all hospitals in Sweden and from 
2001 outpatient visits are included. Validation of the register has shown positive predictive 
values of 85-95 % for diagnoses in inpatient care according to the International Classification 
of Diseases (ICD)97. The presence of personal identification numbers in Sweden allows for 
linkage between registries in populations-based studies. 
 
Surgical treatment 
 
Except for a small number of rectal cancer patients with a complete tumour regression 
following (C)RT, a radical resection of the tumour in rectal cancer is a prerequisite for cure. 
In the last hundred years dramatic improvements have been made in rectal cancer surgery. In 
1908, the British surgeon Miles presented a novel surgical method combining abdominal and 
perineal surgery into abdominoperineal excision (APE)98. Before this new surgical technique 
the local recurrence rates were almost 100 %. Although improved, Miles still reported local 
recurrence rates of 29.5 % and the rates of complication and mortality were substantial99. 
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Because of improved perioperative conditions mortality decreased but local recurrence rates 
remained high throughout the major part of the 20th century.  
The understanding of lymphatic tumour spread along the superior rectal artery in Miles´ 
method, was followed by the subsequent removal of mesorectal lymph nodes en bloc with the 
rectosigmoideum. However, it was not until the 1980s that the importance of lateral tumour 
margins was fully understood19. In 1982 Heald described the concept of total mesorectal 
excision (TME), where the dissection line runs along the MRF and all of the mesorectum is 
removed together with the rectal specimen to decrease tumour involvement of the lateral 
resection margins100. As a result, Heald could show a dramatic decrease in local recurrence 
rates down to 4 %101. Several investigations have confirmed that TME-surgery of good 
quality results in local recurrence rates below 10 %, but also in improved long-term 
survival102-104.  
Pelvic surgery is associated with a high risk of urogenital dysfunction. However, in the last 
decades of the 20th century, Japanese surgeons showed that identification and sparing of 
autonomic nerves (hypogastric nerves, inferior hypogastric plexus, pelvic splanchnic nerves) 
during rectal cancer surgery resulted in better outcomes regarding sexual function and urinary 
voiding105, 106. TME-surgery with autonomic nerve preservation has been shown to decrease 
postoperative urogenital dysfunction without jeopardising long-term oncological outcome107. 
The TME-technique is today the gold standard of rectal cancer surgery in the low and mid 
rectum and is used regardless of what kind of rectal resection that is performed: with 
anastomosis (anterior resection) or without (APE, Hartmann´s operation) and in open as well 
as minimally invasive surgery. However, controversies exit regarding the surgical 
management of tumours in the upper rectum. Since the lymph of the upper rectum drains 
upwards along the superior rectal artery it is reasonable to argue that harvesting the lymph 
node of the lower mesorectum is unnecessary in upper rectal cancer. Furthermore, although 
vast improvements in rectal cancer surgery have been accomplished, complications after 
TME-surgery still constitute a considerable problem and a low anastomosis appears to be 
related to worse quality of life scores108. A partial mesorectal excision (PME) transecting the 
rectum 5 cm below the tumour has been suggested and several reports have shown a better 
functional outcome compared to after TME without compromising local control109-111. In 
contrast, other authors have reported increased local recurrence rates after PME and it appears 
as if the benefit regarding functional outcome in patients undergoing PME is abolished 
following preoperative radiotherapy (RT)112, 113. 
Improvements in perioperative care during the last century have led to better outcomes in 
abdominal surgery. To further reduce the adverse effects of major surgery an Enhanced 
Recovery After Surgery (ERAS) program or “Fast track” surgery was developed in the last 
decades114, 115. The ERAS protocol includes several perioperative interventions that aim to 
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reduce the surgical strain and have been shown to reduce complications and the length of stay 
compared to traditional care116, 117. 
 
Anterior resection (AR) 
Following the introduction of TME the proportion of patients with a permanent stoma after 
rectal cancer surgery was substantially reduced118. In addition, circular stapling devices 
facilitated this development. In faecal continent patients with a rectal tumour without 
sphincter involvement in the low or mid rectum, a low anterior resection (LAR) is preferred. 
A LAR includes the division of the proximal sigmoid colon, TME-dissection and transection 
of the rectum at or immediately above the pelvic floor. A coloanal anastomosis is created, 
usually with the aid of a circular stapling device. The term high anterior resection (HAR) 
originally was used to describe an anterior resection above the peritoneal reflection but has 
more recently been used as an equivalent to PME. In about half of the patients undergoing 
rectal cancer surgery in Sweden an AR is performed2.  
The use of a temporary defunctioning stoma in patients undergoing LAR, has been shown to 
decrease the risk of symptomatic anastomotic leakage and also the need for re-operation 
among patients with anastomotic leakage119. Defunctioning stomas are standard practise in 
many centres and usually stoma closure is undertaken within 3 month after the LAR. 
 
Hartmann´s procedure 
The Hartmann procedure was originally described for obstructive cancer of the left colon120. 
In rectal cancer surgery the Hartmann procedure includes TME or PME but unlike with AR, 
no restoration of bowel continuity. After division of the rectum, the distal colon end is used to 
create a stoma that most often is permanent. The Hartmann operation is mainly considered in 
palliative surgery, in patients with anal incontinence or in situations with impaired healing. It 
is also performed for tumours in the sigmoid colon and for benign diseases such as 
diverticulitis. 
 
Abdominoperineal excision (APE) 
In principal, an APE consists of the removal of the entire rectum and anal canal with the 
construction of a permanent end-colostomy. APE can be sub-divided into four different types: 
intersphincteric APE, conventional APE, extralevator APE (ELAPE) and ischioanal APE121. 
In the intersphincteric APE, the external sphincter and the pelvic floor is left intact and the 
operation is an alternative to the Hartmann procedure in patients with a tumour well above the 
sphincter complex in whom an anastomosis is contraindicated or if the patient suffers from 
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anal incontinence. The advantage of an intersphincteric APE compared to the Hartmann 
procedure is the absence of a rectal stump that can cause postoperative pelvic abscesses122. On 
the other hand, following APE problems with impaired perineal wound healing are common, 
especially after preoperative RT123. 
In a conventional APE the abdominal part ends at the pelvic floor and the perineal part 
includes resection of the anal canal, the sphincter complex and the lower part of the levator 
muscle. The resected specimen shows a waist at the distal border of the mesorectum, above 
the levator muscle124. From this waist and distally where the external sphincter is forming the 
outer border of the excision, the CRM is naturally shorter. Several investigations have showed 
that a conventional APE for low rectal cancers is associated with high rates of CRM 
positivity, local recurrence and poor survival125-127. In 2007 Holm et al. proposed ELAPE as a 
method to decrease the risk of inadvertent bowel perforation and involved lateral margins124. 
In ELAPE the abdominal part ends at the level of the upper border of the coccyx thereby 
keeping the distal mesorectal attachment to the levator muscle. The perineal dissection line 
runs along the outer border of the external sphincter and continues below and along the 
levator muscles until the insertion onto the pelvic sidewall where it is divided. The cylindrical 
specimen resected with ELAPE results in the theoretical benefit of an increased lateral 
margin. In APE the perineal wound usually can be closed primarly whereas an ELAPE 
usually requires a pelvic floor reconstruction with a musculocutaneous flap or a biological 
mesh. Several publications including a review, a meta-analysis and a randomised trial have 
shown favourable outcomes with ELAPE compared to APE with regards to rates of bowel 
perforation, CRM positivity and local recurrence128-131. Other reports however, could not 
show difference regarding these outcomes but a higher rate of wound problems with 
ELAPE132-134. 
In the ischioanal APE, the abdominal part is similar to the ELAPE but instead of following 
the external sphincter, the perineal dissection runs along the fascia of the internal obturator 
muscle. This method is mainly considered for patients with locally advanced tumours 
involving the ischioanal compartment or the perianal skin121. 
 
Lateral lymph node dissection (LLND) 
Controversies regarding whether to define lateral lymph node metastases as localised or 
systemic disease have led to different treatment strategies throughout the world. In Japan 
LLND is recommended for rectal cancer growing below the perineal reflection whereas in the 
western world instead preoperative (chemo-)radiation is recommended11, 135.  
According to a multicentre trial by Fujita et al. where patients with stage II-III rectal cancer 
without lateral lymph node enlargement (> 10 mm) on MRI or CT were randomised to TME 
surgery with or without LLND, patients in the LLND arm had significantly longer operation 
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time (360 vs. 254 min, p < 0.0001), greater blood loss (576 vs. 337 ml, p < 0.001) and a 
tendency of more complications but there were no significant differences regarding male 
postoperative sexual or urinary dysfunction65, 136. The recently published 5-year data from this 
trial showed no significant differences in OS but the local recurrence rates were significantly 
lower in the LLND arm (7.4 % vs. 12.6 %; p = 0.024)137. Furthermore, the proportion of 
lateral recurrences out of all local recurrences were significantly lower in the LLND arm 
compared to in the TME alone arm (15 % vs. 52 %; p = 0.02). In this trial, none of the 
patients received preoperative treatment. An investigation based on data from a Japanese 
nationwide registry reported improved OS (HR 0.85; 95 % CI 0.78-0.93) in rectal cancer 
patients who underwent LLND138. However, in a meta-analysis by Georgiou et al., LLND did 
not significantly improve survival or local recurrence rates but was correlated with higher 
rates of urinary and sexual dysfunction in males139. Although the presence of lateral lymph 
nodes metastases in rectal cancer is associated with inferior prognosis, more data are needed 
to fully understand the role of LLND, especially following preoperative (C)RT67, 68, 140. 
 
Minimal invasive surgery 
Two large randomised multicentre trials (COREAN, COLOR II) have proven superior short-
term outcomes in terms of blood loss, time to recovery, return to bowel function and length of 
stay with laparoscopic vs. open TME with similar rates of CRM positivity and equivalent 
specimen quality141, 142. The 3-year follow up from these trials also showed similar rates of 
OS, DFS and local recurrence143, 144. However, the operation time was significantly longer in 
the laparoscopic group and T4 tumours were not included. Two other randomised trials 
(ACOSOG, ALaCaRT) failed to show non-inferiority with laparoscopic compared to open 
rectal cancer surgery when results regarding CRM, DRM and completeness of TME were 
combined145, 146. Laparoscopic rectal cancer surgery may be justified in experienced centres 
and with good quality outcome data, but otherwise as well as for locally advanced rectal 
cancers, open surgery is preferable. 
Robotic surgery has the same minimal invasive gains as laparoscopic surgery but has features 
that may improve the possibility to perform advanced nerve-sparing surgery in the narrow 
pelvis. There are some studies showing benefit of robotic over laparoscopic rectal cancer 
surgery regarding outcomes and conversion rates but no published data from randomised 
multicentre trials are available147. Furthermore, the robotic technique is associated with high 
costs and therefore more solid data is warranted before it can be widely adopted. 
Transanal TME (ta-TME) is a relatively new technique, which combines laparoscopic 
abdominal surgery and transanal TME-dissection148. It appears to have advantages over 
laparoscopic surgery in male patients with distal tumours, narrow pelvis and high BMI but 
more evidence is required to determine its short-term and long-term benefits149. 
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Local excision 
Transanal endoscopic microsurgery (TEM), endocopic mucosal resection (EMR) and 
endoscopic submucosal dissection (ESD) are local excision techniques for polyps or early 
rectal tumours where the risk of lymph node metastases is low according to MRI and/or EUS. 
The advantage with these types of surgery is the shorter operation time, low grade of 
morbidity imposed and that they usually can be performed without general anaesthesia, which 
makes local excision attractive in fragile patients. However, using these techniques implies a 
risk of positive resection margins and also, engaged lymph nodes are not sufficiently yielded.  
In the Japanese guidelines for colorectal cancer EMR and EMD are recommended for Tis and 
T1 tumours with only slight submucosal invasion since only part of the rectal wall is removed 
with these techniques135. ESD is more demanding for the endoscopist and associated with 
higher complication rates and longer operation time but also with lower rates of local 
recurrence and more en bloc resections, especially for larger lesions (≥ 2 cm)150.  
TEM includes a full-thickness excision of the rectal wall and suturing of the defect but 
without resection of the mesorectum. TEM compared to TME for T1 tumours results in 
significantly less morbidity and mortality and shorter length of stay but also higher local 
recurrence rates151. The higher rates of local recurrence after TEM may also increase the 
proportion of patients who need to undergo more advanced surgery with APE after TEM 
surgery compared to if TME with LAR had been performed for the primary tumour152. 
 
Surgery for locally advanced and locally recurrent rectal cancer 
The surgical principles guiding surgery for primary rectal cancer also apply to locally 
advanced and locally recurrent rectal tumours. However, surgery for advanced rectal tumours 
also imposes the need for dissection outside the TME planes and resection of other involved 
organs. Consequently, a need for reconstructive surgery is common, complication rates 
reported are high (48-68 %) and mortality is not negligible153-158. Surgery is the only curative 
option for locally advanced or locally recurrent rectal cancer and oncological outcomes are 
largely dependent on the ability to perform radical resections159. Although improvements 
appear to have been made, the rate of R1 or R2 resection still ranges between 23-46 % and 
according to a meta-analysis the range of median survival for R0, R1 and R2 resection is 28-
90 month, 12-50 month and 6-17 months, respectively86, 153, 154, 156, 157, 159. 
What is defined as locally advanced tumours differs between investigations, making 
comparison of results difficult. Also, the management of patients with locally advanced or 
locally recurrent rectal cancer displays a wide variation between centres throughout the world 
and there are no guidelines that fully cover the care of these patients. The need for complex 
treatment decisions and arduous surgery for this patient group demands a multidisciplinary 
approach in devoted centres to improve outcome and patient selection. Indeed, in a recent 
 35 
 
publication from the Royal Marsden Hospital, R0 resection was achieved in 93 % of patients 
with locally advanced or recurrent colorectal cancer after a structured multidisciplinary 
approach in a highly specialised centre160. 
 
Complications after rectal cancer surgery 
Except for the local excision techniques, rectal cancer surgery is a major procedure rendering 
considerable morbidity. In addition, a substantial proportion of rectal cancer patients are 
treated with (C)RT that further increases complication rates. Morbidity after rectal cancer 
surgery can be divided into postoperative short-term complications and long-term functional 
outcome. Since the management of rectal cancer surgery as well as the definition and 
registration of morbidity vary, there is diversity in complication rates reported. 
Short-term complications 
Short-term complications include anastomotic leakage after AR, wound problems, 
intraabdominal infection, ileus, medical adverse events such as cardiac and respiratory 
complications and death. According to a review by Paun et al., including studies with patients 
who had undergone open or laparoscopic AR or APE, the rates of anastomotic leakage were 
11 % (AR), pelvic sepsis 12 %, wound infection 7 % and mortality 2 %161. In the COLOR II 
trial there were no significant difference between the laparoscopic and open group concerning 
overall morbidity, anastomotic leakage, wound infection, postoperative ileus or mortality but 
the COREAN trial reported a lower frequency of wound discharge in the laparoscopic group 
(1.2 vs. 6.5 %, p = 0.020)141, 142. Perineal wound complications after APE constitutes a major 
problem and has been reported in 20-38 % after conventional APE and in 38-46 % after 
ELAPE129, 132, 162. 
Male sex, malnutrition, advanced age, comorbidity, smoking, high BMI, preoperative (C)RT 
and advanced tumour stage have been identified as risk factors for adverse short-term 
outcomes after rectal cancer surgery163-166. Beside prolonged hospital stay, increased suffering 
and mortality caused by postoperative complications there are also indications of inferior 
oncological outcome following anastomotic leakage167. 
Long-term complications 
Low anterior resection syndrome (LARS) refers to anorectal dysfunction following anterior 
resection. The symptoms include faecal incontinence and urgency but also fragmentation of 
stool and difficulty to defecate. According to a review by Bryant et al., the reported 
prevalence of incontinence is between 0-71 % and of evacuatory disorder 12-74 % after 
anterior resections168. Because of the diversified terminology and difficulties in result 
comparison, a LARS-score composed of 5 questions was developed and validated in 
Denmark169. Preoperative (C)RT, TME vs. PME, anastomotic leakage, age ≤ 64 years and 
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female sex have been shown to correlate to inferior anorectal function in terms of a high 
LARS-score111. 
Although improved by TME surgery and nerve sparing dissection, the prevalence of erectile 
dysfunction (14-80 %), and retrograde ejaculation (20-40 %) in men and decreased 
lubrication (15-57 %) and dyspareunia (25-59 %) in women after rectal cancer surgery 
remains considerable107, 136, 170-173. Moreover, even when nerve damage clearly can be avoided 
other factors than the surgery itself, such as preoperative RT, advanced age, comorbidity, the 
presence of a stoma and faecal incontinence increases the risk of postoperative sexual 
dysfunction136, 172, 173. Also, the overgrowth of locally advanced tumours can make nerve 
sparing surgery impossible. Damage to the autonomic nerves during pelvic surgery also 
increases the risk for urinary dysfunction. From the Dutch TME trial postoperative 
incontinence and difficulties in emptying the bladder was reported in 38 % and 31 % of the 
patients174. 
Patients undergoing APE or Hartmann´s procedure will receive a permanent colostomy and a 
large proportion of patients will have a temporary diverting ileostomy after an AR. Stoma 
formation is associated with many complications. Stoma necrosis, retraction, prolapse, 
stenosis and hernia is relatively common for both ileostomies and colostomies while fluid and 
electrolyte imbalances, leakage and peristomal skin problems is associated chiefly with 
ileostomies due to their more frequent and watery stools175. Beside the risk of morbidity 
imposed by an ileostomy, the time to stoma closure can be prolonged for several reasons and 
in up to one fourth of the patients the ileostomy will be permanent176, 177. Also, the morbidity 
after stoma closure is not negligible178.  
 
Preoperative radiotherapy (RT) 
 
RT induces cell death through damage to the DNA and has the greatest effect on proliferative 
cells in the mitotic phase. Since cancer tumours have proportionally more cells undergoing 
mitosis and also because DNA-repair is impaired, tumour cells are more sensitive to RT than 
cells in normal tissue. In most tumour forms, including adenocarcinoma of the rectum, cell 
death continuous long after administration of radiation. The purpose of RT in rectal cancer is 
twofold: to kill tumour cells near the primary tumour that may not be resected by standard 
rectal cancer surgery (TME) and to induce downsizing and downstaging of the tumour, 
thereby increasing the rates of R0 resection, sphincter preservation and local control. The 
effect of RT on rectal tumours and the risk of damage to normal tissue depends on the total 
dose in Gray (Gy), the dose per fraction, the number of fractions, irradiated volume and time 
interval between RT and surgery179. 
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There has been a long-lasting controversy on whether pre- or postoperative RT should be 
used, optimal dose and fractionation of RT, timing of surgery, and the gain of chemotherapy 
added to RT for rectal cancer, to achieve the best oncological outcomes and minimise RT-
induced morbidity. In recent years, it has also been debated if it is reasonable to try to 
accomplish complete tumour response and thereby organ preservation with intense CRT 
alone. 
 
Pre- vs. postoperative (C)RT 
Several large randomised European trials have demonstrated the benefit of preoperative RT. 
These trials have demonstrated a reduction in local recurrence rates of 41-56 % with 
preoperative RT and surgery compared to surgery alone180-186. This risk reduction persisted 
also in the trials where TME surgery was performed with local recurrence rates of about 5 % 
after preoperative RT180, 186. Other trials comparing preoperative (C)RT and postoperative 
(C)RT showed local recurrence rates of 4-13 % and 11-22 %, respectively and with less 
radiation induced toxicity if (C)RT were given preoperatively184, 186, 187. Based on these 
investigations the preoperative (C)RT regime has become the gold standard in Europe as in 
many other parts of the world11. In Northern America (C)RT for many years was delivered 
postoperatively based on histopathological staging. Nowadays however, with enhanced 
pretherapeutic staging (i.e. MRI), preoperative CRT is recommended for stage II-III disease 
according to the National Comprehensive Cancer Network (NCCN) Guidelines in the U.S.93. 
In the early Swedish Rectal Cancer Trial, patients randomised to preoperative RT had better 
OS than patients randomised to direct surgery (58 % vs. 48 %; p = 0.004)181. However, other 
trials, especially since the introduction of TME surgery, have not been able to reproduce this 
result and RT is now considered to be of importance mainly regarding achieving better local 
control186, 188. 
 
Dose and fractionation of RT 
Numerous regimens of preoperative RT for rectal cancer have been proposed but it is usually 
administered as short course hypofractionated RT or long course conventionally fractionated 
RT. In short course RT 5 Gy is given daily during 5 days (5 x 5 Gy). In long course RT 1.8-2 
Gy is given in 23-28 fractions during 4-5 weeks and often combined with chemotherapy 
(CRT)189. The late side effects of 5 x 5 Gy have been explored and seem to have decreased 
over time due to improvements in radiation technique, but is less investigated concerning 
preoperative long course RT190. Two trials (TTROG Trial, Polish Colorectal Study Group 
trial) randomising patients with T3 and T3/4 rectal cancers to preoperative short course RT or 
preoperative long course (C)RT, were unable to demonstrate any significant differences 
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regarding late toxicity, local recurrence rates or survival191, 192. However, in the Polish trial the 
rate of CRM positive resection was significantly higher in patients who received short course 
RT (12.9 % vs. 4.4 %; p = 0.017).  
Since there is no clear evidence regarding the superiority on outcome of either RT regime, 
there is a variation in practise throughout the world. Due to the short duration and because it 
is less resource demanding, 5 x 5 Gy is preferred in the north-western Europe. In other 
countries, because of the known risks of late toxicity with 5 x 5 Gy and, possibly, also due to 
economic gains in privately financed health care with more treatment given during several 
days, long course (C)RT is mainly used189. 
 
Timing of surgery 
Traditionally preoperative long course (C)RT has been followed by a delay of 6-8 weeks 
before surgery is performed to reduce the effect of acute radiation toxicity, to increase tumour 
regression and achieve downstaging193. According to a meta-analysis by Martin et al., patients 
with a pathological complete response (pCR) compared to patients with incomplete response 
after preoperative CRT, had lower local recurrence rates (OR 0.25; p = 0.002) and improved 
OS (OR 3.28; p = 0.001)194. In another recently published meta-analysis by Petrelli et al. 
investigating the effect of prolonged delay after preoperative CRT, the proportion of patients 
with pCR increased from 13.7 % to 19.5 % if the delay was more than the usual 6-8 weeks195. 
In this meta-analysis, there were no significant associations between length of delay and rates 
of anastomotic leakage, wound complications, R0 resections, sphincter preservation or 
survival outcomes. A report from the Dutch TME trial, randomising rectal cancer patients to 
TME surgery with or without preoperative RT 5 x 5 Gy, showed a downsizing effect in the 
RT group but there were no significant differences regarding T or N stage196. However, all 
patients receiving RT in this trial had direct surgery (within 10 days from the start of RT) and 
it is reasonable to believe that the downstaging effect of RT continuous also after the first 
week. The Swedish Rectal Cancer Trial demonstrated evidence of tumour regression after 
preoperative short course RT if surgery was delayed more than 10 days after the start of RT 
and this finding was confirmed also in other investigations186, 197, 198. 
The three-armed Stockholm III trial randomised patients with resectable rectal cancer to short 
course RT with immediate surgery, short course RT with delayed surgery after 4-8 weeks and 
long course RT with delayed surgery after 4-8 weeks199. An interim analysis of this trial 
including only patients receiving short course RT, showed a significantly higher rate of pCR 
(11.8 % vs. 1.7 %; p = 0.001) and Dworak grade 4 tumour regression (10.1 % vs. 1.7 %; p < 
0.001) in the delay group compared to the immediate surgery group200. In another recent 
publication from this trial, no significant differences regarding rates of local recurrence, 
distant metastasis and OS were reported199. In a pooled comparison of the two short course 
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arms, delayed surgery was associated with higher rate of acute radiation toxicity (OR 24.67; 
95 % CI 3.31-138.72) but lower rate of postoperative complication (OR 0.61; 95 % CI 0.45-
0.83) compared to direct surgery. 
 
RT vs. CRT 
In the TTROG and Polish trials the use of concomitant chemotherapy with preoperative long 
course RT did not influence oncological outcome or late toxicity in the comparison with 
preoperative short course RT191, 192. In two other trials (EORTC trial, FFCD trial) where 
patients with resectable T3/4 rectal cancer were randomised to preoperative long course RT 
with or without chemotherapy, the rate of local recurrence was significantly reduced if 
chemotherapy was added to RT whereas no effect was seen on OS201, 202. In the FFCD trial 
where chemotherapy was delivered concurrent with preoperative RT, the 5-year local 
recurrence rates were 16.5 % vs. 8.1 % (p = 0.004), the rate of pCR 11.4 % vs. 3.6 % (p < 
0.001) and acute grade 3-4 toxicity 14.6 % vs. 2.7 % (p < 0.001) in the CRT arm compared to 
the RT arm. In the 4-armed EORTC trial randomising patients to preoperative RT alone or 
with chemotherapy concomitant to RT and/or postoperatively, the local recurrence rates were 
similar irrespective of timing of chemotherapy but patients who received chemotherapy had 
lower local recurrence rates than patients in the RT alone arm (7.6-9.6 vs. 17.1 %; p = 0.002). 
The LARCS trial, randomising 184 patients with non-recectable T4 rectal cancer and 25 
patients with locally recurrent rectal cancer to long course preoperative RT with or without 
concurrent chemotherapy, showed a benefit of adding chemotherapy regarding R0 resections 
(84 % vs. 68 %; p = 0.02), pCR (16 % vs. 7 %; p = 0.04), local control (82 % vs. 67 %; p = 
0.03), distant metastasis (26 % vs. 39 %; p = 0.04) and cancer-specific survival (72 % vs. 55 
%; p = 0.02) although acute grade 3-4 toxicity was more common than after RT alone (29 % 
vs. 6 %; p = 0.001)203. Thus, CRT appears to increase local and systemic control in patients 
with locally advanced tumours, albeit with increased acute toxicity whereas for patients with 
intermediate rectal cancer the evidence is more incongruent. The recommendations for these 
tumours vary accordingly11, 92, 93, 135, 204.  
Recently published data from a randomised trial comparing conventionally fractionated CRT 
with preoperative 5 x 5 Gy and upfront chemotherapy before surgery for fixed T3/4 rectal 
cancer, showed no significant differences in pCR, postoperative complications, R0 resection 
rates, local recurrence rates or DFS but less acute toxicity (75 % vs. 83 %; p = 0.006) and 
better 3-year OS (73 % vs. 65 %; p = 0.046) in the 5 x 5 Gy arm205. The multicentre RAPIDO 
trial, recently closed for inclusion, with a similar design but with longer preoperative 
chemotherapy in the 5 x 5 Gy arm, aims to further investigate the effectiveness and safety of 
combined preoperative short course RT and full-dose chemotherapy for locally advanced 
rectal cancer206.  
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The most commonly used chemotherapeutic agent in CRT for rectal cancer is 5-flurouracil (5-
FU) administered intravenously, but the oral drug Capecitabine may also be used having the 
same radiation sensitisation properties. CRT with combinations of chemotherapeutic agents 
has been investigated in several trials although without demonstrating any clear benefit over 
single-agent chemotherapy regimens189. 
 
Organ preservation 
The knowledge regarding tumour response and the downsizing and downstaging effect of 
preoperative treatment has rendered an increasing interest in exploring treatment regimens 
aiming at achieving organ preservation. A pCR is known to occur in approximately 20 % of 
rectal cancer patients following preoperative CRT and is associated with improved local and 
distant control and survival194, 207. Tumour factors correlated to pCR include low grade of 
differentiation, small tumour size, low cT or cN stage, high radiation dose and longer delay of 
surgery (> 6-8 weeks)208.  
From a series of 265 patients with resectable distal rectal cancer treated with preoperative 
CRT, Habr-Gama et al. reported that 8 weeks after completion of CRT, 71 (26.8 %) patients 
had a clinical CR (cCR), assessed by a combination of digital rectal exam (DRE), endoscopy, 
EUS, biopsy and CT209. The patients with a cCR were followed by frequent clinical 
investigations and patients with incomplete response underwent surgery. In the cCR group 
two patients developed local tumour re-growth that was treated locally and three patients 
developed distant metastasis. The 5-year OS in this group was 100 % although this was based 
only on the 28 (39 %) patients that remained in follow-up. Some other groups have shown 
similar promising survival outcomes and a relatively low proportion of patients with an initial 
cCR who later develop a need for salvage surgery, but the results reported overall are 
heterogeneous and based chiefly on small retrospective series210, 211. There is a growing 
interest in using TEM as a part of organ preservation programmes for rectal cancer. In a phase 
II trial including 79 patients with T2N0 cancer in the distal rectum that received CRT 
followed by TEM, the 3-year DFS was 86.9 % according to the per-protocol analysis and 8 
patients had a local recurrence212.  
Numerous non-operative strategy programs have been proposed (“Watchful waiting”, “Wait 
and watch”, “Watch and wait”, “Wait and see”) with differences regarding patient inclusion 
(T stage), choice and timing of preoperative CRT, definition of cCR, timing and modality of 
clinical response assessment and follow-up programme, but there is little evidence on the 
optimal setting213. CRT is associated with both acute toxicity and late adverse effects and 
there is a risk of overtreatment of patients with early tumours who would be recommended 
primary surgery outside the organ preservation programmes. Moreover, there is concern 
regarding outcomes in those patients needing salvage surgery because of local regrowth in 
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such a programme211. Furthermore, although there are obvious advantages with the omittance 
of major surgery, the follow-up programme for patients with a cCR is resource demanding. 
Since there is a lack of evidence based on randomised trials on all aspects of organ 
preservation programmes, patients eligible for such programmes should be treated within 
clinical trials213. 
 
Adverse events after radiotherapy  
 
Acute toxicity 
The acute adverse effects after preoperative (C)RT depends on the target volume of radiation, 
adjacent organ included in the radiation field and regime of RT and chemotherapy. The 
frequency of acute adverse effects has likely decreased with improved radiation technique. 
Symptoms of acute toxicity related to (C)RT include fatigue, nausea, diarrhoea, proctitis, 
perineal dermatitis, pelvic and perineal pain and urinary problems201, 214, 215. Chemotherapy in 
rectal cancer patients is associated with fever, infections, stomatitis, skin reactions and 
cytopenia201, 214. Contrary to the late adverse effects due to (C)RT, acute toxicity is usually 
transient. The Common Terminology Criteria for Adverse Events (CTCAE) developed by the 
National Cancer Institute (NCI), is used to grade the severity of adverse events after 
oncologic treatment (Table 5)216. 
 
Table 5. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0216. 
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated 
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-
appropriate instrumental ADL 
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling limiting self care ADL 
Grade 4 Life-threatening consequences; urgent intervention indicated 
Grade 5 Death related to adverse events 
 
In a Cochrane review from 2013 including 5 trials with rectal cancer patients randomised to 
preoperative RT or CRT, there was a significantly lower proportion of grade 3-4 toxicity in 
patients treated with RT than CRT (5.1 % vs. 14.9 %; OR 4.1; 95 % CI 1.68-10)217. Although, 
the included trials were heterogeneous regarding the RT regime, data from a more recently 
published randomised trial confirmed the lower rate of grade 3-4 toxicity with 5 x 5 Gy vs. 
CRT (1.9 % vs. 27.1 %; p < 0.001)214. Even in trials comparing conventional CRT and 5 x 5 
Gy with preoperative consolidation chemotherapy, CRT is correlated to significantly more 
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acute toxicity205. 
 
Late adverse effects  
Several of the late adverse effects associated with RT are common also after rectal cancer 
surgery alone because of pelvic nerve injury and bowel reconstruction, but it appears that RT 
has an additive effect on these symptoms. According to a review by Birgisson et al., bowel 
dysfunction after AR is more common after preoperative RT than after surgery alone with 
symptoms including faecal incontinence (14-72 % vs. 3-38 %), increased stool frequency (20-
83 % vs. 8-23 %), urgency (53 % vs. 0 %) and evacuation difficulties (52 % vs. 36 %)190. RT 
is also associated with a higher frequency of small bowel obstruction and symptoms of 
urinary dysfunction including incontinence, increased frequency and chronic cystitis218. 
Furthermore, increased rates of erectile, ejaculatory and overall sexual dysfunction among 
male rectal cancer patients after RT have been reported173, 190, 219, 220. According to recently 
published data, RT also results in testicular failure increasing the risk of hypogonadism221. In 
females, RT for rectal cancer has been associated with dyspareunia, vaginal dryness and 
overall sexual dysfunction173, 222.  
From an investigation including patients from the Uppsala trial and the Swedish Rectal 
Cancer Trial, Birgisson et al. reported an increased risk of secondary cancers located not only 
in the pelvis, after RT for rectal cancer223. However, a Canadian report from the Surveillance, 
Epidemiology, and End Results (SEER) registry including 20,910 patients previously treated 
for rectal cancer did not demonstrate any significant difference in the risk of secondary cancer 
overall, but the risk of cancers in the uterine corpus and cervix was increased (HR 2.5; 95 % 
CI 0.48-0.84) and the risk of prostate cancer was decreased (HR 0.63; 0.48-0.84) in irradiated 
compared to non-irradiated patients224. Also in a study analysing 13,457 rectal cancer patients 
from the SCRCR and from five randomised trials, there were no overall impact of irradiation 
on the risk of secondary cancer but a decreased risk of prostate cancer (HR 0.68; 95 % CI 
0.51-0.91)225. 
Although the knowledge regarding late adverse effects after short course RT is profound, less 
is known about CRT in this matter. In two trials randomising patients to preoperative short 
course RT or CRT, there were no significant differences regarding late adverse effects191, 192. 
In a retrospective analysis of patients receiving preoperative 5 x 5 Gy or CRT, the health-
related quality of life (HRQL) was similar apart from more nausea/vomiting (p < 0.01) and 
less satisfaction with urinary function in patients who received CRT (p < 0.01)226. 
 
Preoperative treatment according to clinical tumour stage 
To facilitate preoperative treatment selection at the MDT conferences, guidelines have 
recommendations based on the extent of local tumour growth. In the guidelines issued by the 
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NCCN, recommendations are based merely on T and N stage where patients with T1-2 N0 
tumours should undergo surgery alone and patients with T3-4 and/or N1-2, preoperative 
treatment (CRT) before surgery93. The Japanese guidelines reserve preoperative CRT for 
patients with tumours growing below the peritoneal reflection and/or judged primarily 
unresectable135. In several European guidelines, other known predictors of recurrence readily 
assessed by MRI, such as tumour height, MRF involvement and EMVI status, are used for the 
guidance of preoperative treatment and the categorisation of tumours into very early, early, 
intermediate and locally advanced are commonly adopted11, 92, 204.  
In a publication from 2008, Blomqvist and Glimelius classified rectal cancer into “good”, 
“bad” or “ugly”, based on pretherapeutic investigation with MRI227. According to this paper, 
the proportion of rectal cancer judged to be “good” is 20-40 %, “bad” 40-60 % and “ugly” 10-
20 % and the local recurrence risk is < 10 %, 10-20 % and 20-100 %, respectively3, 227. The 
recommendation regarding preoperative treatment for each tumour category in that article is 
consistent with the Swedish guidelines for colorectal cancer, although the recommendation of 
preoperative 5 x 5 Gy is added in patients with EMVI positive tumours3. 
 
Table 6. “Good”, “bad” and “ugly” rectal cancer and recommended preoperative treatment 
according to Blomqvist and Glimelius227. 
 Tumour stage category  
Good Bad Ugly 
Mid/upper rectum (> 5 cm) 
T1-3b 
 
Low rectum (≤ 5 cm) 
T1-2, T3a 
 
Mid/upper rectum (> 5 cm) 
T3c/d 
 
Low rectum (≤ 5 cm) 
T3b 
T4 with overgrowth to prostate, 
seminal vesicles, base of urinary 
bladder, pelvic sidewalls or floor, 
sacrum 
 
N0 T4 with peritoneal or vaginal 
involvement only 
Positive lateral lymph nodes 
MRF clear  MRF positive 
 N1-2  
 MRF clear  
   
Primary surgery Preoperative 5 x 5 Gy with 
immediated surgery 
Preoperative CRT or  
5 x 5 Gy with delayed surgery 
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Adjuvant chemotherapy 
 
Adjuvant (postoperative) chemotherapy for stage II colon cancer with risk factors and stage 
III colon cancer has been shown to increase DFS and is routinely used in colon cancer 
management228, 229. In contrast, there is little evidence regarding adjuvant chemotherapy in 
rectal cancer. Exploring the benefit of adjuvant treatment in rectal cancer is difficult since 
many rectal cancer patients receive preoperative (C)RT and this may alter postoperative 
tumour stage and indications for adjuvant chemotherapy. In a meta-analysis, Breugom et al. 
included 4 trials with rectal cancer patients receiving preoperative (C)RT that were randomly 
assigned to adjuvant chemotherapy or not230. No significant differences were shown regarding 
survival or distant recurrence, although patients with upper rectal cancers that received 
adjuvant chemotherapy had better DFS (HR 0.59; 95 % CI 0.40-0.85) and fewer distant 
recurrences (HR 0.61; 95 % CI 0.40-0.94). In the Swedish national colorectal cancer 
guidelines, adjuvant chemotherapy for rectal cancer is mainly recommended for un-irradiated 
stage II tumours with risk factors and stage III tumours, especially in the upper rectum3. 
 
Age and comorbidity 
 
The knowledge on how to best treat rectal cancer patients with advanced age or comorbidity 
is scarce since the inclusion of these patients in clinical trials is limited231. As a result of this, 
preoperative treatment recommendations in guidelines taking patients frailty into 
consideration are meagre. Since performance status is less often reported than age, the 
evidence is even sparser concerning comorbidity. As life expectancy increases and 
comorbidity as well as rectal cancer incidence increases with age, more frail patients will be 
considered for rectal cancer therapy.  
Treatment selection regarding patients with high age or comorbid conditions is complex. 
Omittance of rectal cancer treatment will lead to inevitable death and is associated with 
substantial suffering and less extensive treatment increases the risk for recurrence. On the 
other hand, treatment related morbidity and mortality is increased in the elderly and in 
patients with comorbidity. It has been reported that advanced age in patients that undergo 
rectal cancer surgery correlates to a lower proportion of abdominal surgery (i.e. more local 
excisions) and R0 resections, more postoperative complications, more permanent ostomies 
and a higher frequency of postoperative mortality232-235. Other authors failed to demonstrate 
any significant difference concerning postoperative morbidity between young and old 
patients236. Numerous population-based investigations have demonstrated that being old or 
having comorbidity is associated with significantly lower probability of receiving RT for 
rectal cancer232, 233, 237-240. Although improvements have been reported over time, rectal cancer 
patients with advanced age or comorbidity have worse survival outcomes164, 235, 241. However, 
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several investigations have shown that elderly rectal cancer patients who receive RT have 
significantly lower local recurrence rates and in some reports also improved survival 
compared to patients in whom RT is omitted234, 242, 243. 
There is little is knowledge regarding tolerability of CRT in frail patients. In a study by 
Margalit et al. 36 rectal cancer patients aged 75 years or older and in whom comorbidity was 
judged as moderate or severe in 17 of the patients, were investigated regarding treatment 
deviation during CRT244. Some 33 patients completed the RT but in 9 of the patients a 
temporary break in RT was required and only 14 patients completed ≥ 4 months of 
chemotherapy. In another investigation where patients ≥ 70 years received preoperative RT or 
CRT, 37 % of the patients treated with chemotherapy required dose modification or 
discontinuation245. There were no differences in 3-year OS after RT or CRT but advanced 
comorbidity was associated with worse OS (71.1 % vs. 26.4 %, p = 0.0003). Likely, RT is 
preferable to CRT in frail patients with rectal cancer when preoperative treatment is indicated 
although there are reports showing relatively low rates of dose reduction or discontinuation of 
CRT in elderly rectal cancer patients246. Short course RT with delayed surgery may be a 
useful alternative in aged or comorbid patients with locally advance rectal cancers198.  
The assessment of comorbidity in cancer care is important in the guidance of optimal 
treatment for the individual patient. Ideally, a comorbidity measure should be simple to 
perform, not time-consuming and valid in predicting outcomes. Traditionally oncologists 
have used the Karnofsky or the Eastern Cooperative Oncology Group (ECOG) performance 
status scores to assess disease progression and determine appropriate treatment247, 248. More 
recently the Comprehensive Geriatric Assessment (CGA) has gained popularity in guiding 
cancer management among the elderly249. However, these assessment tools presume a clinical 
evaluation and especially CGA is rather extensive and resource demanding.  
Several comorbidity measures have been developed allowing for administrative data to be 
used, the most cited being the Charlson Comorbidity Index (CCI)250, 251. Originally, Charlson 
et al. used the information from a cohort of 559 patients admitted to the medical service at a 
New York Hospital, to predict the 1-year relative risk (RR) of death depending on each 
medical condition. Using the number and the seriousness of the comorbid disease as 
measured by the RR, a weighted index was created where the risk of death increased with 
each score. The CCI has been validated in several investigations, also using the ICD diagnosis 
codes from medical records250. Despite the fact that it was developed 30 years ago and the 
prognosis for different medical conditions likely has improved, the CCI is widely used also in 
rectal cancer research due to its simplicity regarding information retrieval237, 239, 241, 250.  
In the SCRCR there has previously been no recording of CCI or other comorbidity measures. 
Since 2007 the American Society of Anesthesiologists (ASA) physical status classification is 
registered but the knowledge regarding the reporting of this variable in the SCRCR and its 
validity in evaluating comorbidity in rectal cancer patients is limited252.  
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AIMS OF THE THESIS    
 
Overall aim 
To optimise preoperative treatment selection in rectal cancer, thereby improving long-term 
oncological outcome and minimising treatment-associated morbidity. 
 
Specific aims 
Paper I 
To investigate patient characteristics affecting the selection to preoperative radiotherapy and 
whether non-relevant treatment selection occurs. 
Paper II 
To assess the impact on long-term outcomes in patients with advanced age and comorbidity 
when selected to preoperative radiotherapy. 
Paper III 
To evaluate adherence to pretherapeutic MRI protocol standards and the relation between 
MRI interpretation of images and preoperative treatment selection. 
Paper IV 
To explore if MRI characteristics in primary rectal cancer can predict oncological outcome 
after curatively intended surgery for local recurrence and also the localisation of the local 
recurrence. 
To investigate selection to preoperative treatment for the primary tumour in relation to MRI 
and the effect on oncological outcome after curatively intended treatment for local recurrence. 
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PATIENTS AND METHODS   
 
Table 7. Study cohorts in the thesis. 
Paper Study cohort 
Inclusion 
period 
Number of patients 
    
I 
All rectal cancer patients undergoing 
abdominal surgery in the Stockholm-
Gotland region (SCRCR) 
2000-2010 2619 
    
II 
Stage I-III rectal cancer patients undergoing 
abdominal surgery in the Stockholm-
Gotland region (SCRCR) 
2000-2010 2300 
    
III 
Consecutive rectal cancer patients 
undergoing abdominal surgery in the 
Stockholm-Gotland region (SCRCR) 
2010 94 
    
IV 
Patients undergoing curatively intended 
surgery because of locally recurrent rectal 
cancer at Karolinska University Hospital  
2003-2013 54 
    
 
Paper I 
 
In this population-based cohort study all rectal cancer patients undergoing elective abdominal 
resection from January 2000 to December 2010 in the Stockholm-Gotland area of Sweden 
were included. Data was retrieved from the SCRCR regarding patient and tumour 
characteristics, treating unit, surgery and preoperative treatment. Before 2007 reporting to 
SCRCR concerning preoperative treatment was limited to delivered RT or not. From 2007 the 
SCRCR was expanded allowing for more data to be analysed including discussion at a MDT 
conference, BMI, ASA, pretherapeutic clinical tumour stage and dose and fractionation of 
preoperative RT. Patients were divided by time period into three groups: 2000-2002, 2003-
2006 and 2007-2010. Age was categorised into < 65 years, 65-79 years and ≥ 80 years. 
In a subgroup analysis of patients operated 2007-2010 a simplified three-tier tumour stage 
description was composed. This was an adaption of previous classifications with early, 
intermediate and locally advanced tumours and based on tumour level, cT and cN stage 
 50 
 
(Table 8)11, 227. The clinical tumour stage was then related to selected treatment regime: 
surgery alone, preoperative short course RT or preoperative CRT. During this study period 
two trials were ongoing. The Stockholm III trial randomised patients with resectable rectal 
cancer to short course RT with immediate or delayed surgery or to long course RT199. Since 
all patients participating in the Stockholm III were eligible to short course RT they were 
considered as selected for short course RT in this study. Patients included in the Expert C 
trial, randomising patients to preoperative CRT with or without cetuximab were considered to 
have received preoperative CRT253. Patients with missing data, distant metastases or 
preoperative treatment regimens not listed above were excluded from this subgroup analysis. 
 
Table 8. Tumour staging based on tumour level, T and N stage 2007-2010. 
Tumour stage category 
Early Intermediate Locally advanced 
   
cT1-2 cT1-2 cT4 
cN0 cN1-2 cN0 
any Tumour level any Tumour level Tumour level ≤5 cm 
   
cT3 cT3 cT4 
cN0 cN0 cN1-2 
Tumour level >5 cm Tumour level ≤5 cm any Tumour level 
   
  cT3   
 cN1-2  
 any Tumour level  
   
 cT4  
 cN0  
  Tumour level >5 cm   
   
 
Data on in-patient care for all patients five years prior to the rectal cancer diagnosis were 
retrieved from the Swedish National Patient Register. Main and secondary diagnoses 
according to ICD-9 and ICD-10 were collected to classify comorbidity into three groups using 
the CCI: CCI score 0, 1 or ≥ 2251. The rectal cancer diagnosis was not included in the CCI 
score. Data from the two registries were merged for the analyses. 
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Statistical analysis 
To determine differences between the three periods of time the Anova F-test and the Chi-
square test were used for continuous and categorical variables, respectively. To detect factors 
associated with delivery of preoperative treatment, univariable logistic regression analyses 
were performed whereby odds ratios (OR) were calculated. A multivariable model included 
age, gender and variables based on a significance level of p < 0.1: tumour level, CCI score, 
hospital volume, year of surgery and in the subgroup analysis of the 2007-2010 cohort also cT 
and cN stage. To test for trends Wald test was used. 
P–values of < 0.05 were considered statistically significant in all studies. In all papers Stata® 
version 12.0 statistical software package (Stata Corp LP, College Station, Texas, USA) was 
used to perform the statistical analyses. 
 
Paper II 
 
The cohort of 2619 patients from paper I was used for this population-based study. Patients 
with synchronous distant metastases were excluded. Data retrieval from the SCRCR was 
extended with information regarding pTNM stage, local or systemic recurrence and death. 
pTNM stage was categorised into pTNM stage I-II or III. Outcome measures included local 
recurrence rates, DFS and OS. DFS was calculated using the time interval from primary 
surgery to local or systemic recurrence or death from any cause and OS using the time from 
primary surgery to death from any cause. 
 
Statistical analysis 
Differences in proportions were analysed using the Chi-square test and for continuous 
variables Student´s t test were used. The Kaplan-Meier method was used to assess rates of 
local recurrence, DFS and OS and differences between groups were analysed with the log 
rank test. To determine the effect of co-variables on outcome, Hazard ratios (HR) were 
calculated by univariable Cox regression analyses. In a multivariable model co-variables with 
a significance level of < 0.1 were included. Age and comorbidity was stratified into 
dichotomous variables and further analysed separately by univariable and multivariable Cox 
regression. Wald test was used for trends.   
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Paper III 
 
This study included 100 consecutive patients who underwent elective abdominal rectal cancer 
surgery from January to June 2010 in the Stockholm-Gotland region and had undergone a 
pretherapeutic MRI according to the SCRCR. Preoperative and pretherapeutic MRI reports 
and investigations and also information on adherence to protocol standards in rectal cancer 
MRI were obtained for all patients from nine different hospitals. The images were 
retrospectively re-evaluated by a radiologist specialised in pelvic MRI and the results of the 
re-evaluation were compared to the information in the original reports. Twenty of these MR 
images that were judged necessary to discuss, were re-evaluated a second time by an 
experienced MRI-radiologist specialised in rectal cancer MRI. Information on patient 
characteristics, preoperative treatment and surgery were retrieved from the SCRCR. 
According to a previous classification, all tumours were classified into early, intermediate or 
locally advanced based on the original report and the re-evaluation separately (Table 9)227. 
The tumour stage based on the original report and the re-evaluation were related to both 
preoperative treatment selected (no preoperative treatment, 5 x 5 Gy or CRT) and to 
recommendations from the Swedish guidelines for colorectal cancer3. As in the first two 
studies, patients included in the Stockholm III trial were considered as selected for short 
course RT199. 
 
Table 9. Tumour stage description based on clinical findings and MRI. 
Tumour stage category 
Early Intermediate Locally advanced 
   
Distance from anal 
verge > 5 cm 
T1-T3b 
Distance from anal 
verge > 5 cm 
T3c/d 
T4 
   
Distance from anal 
verge ≤ 5 cm 
T1-T3a 
Distance from anal 
verge ≤ 5 cm 
T3b 
Positive lateral lymph 
nodes 
   
N0 
T4 with peritoneal, or 
vaginal involvement 
only 
MRF positive 
   
MRF clear N1/2  
   
 MRF clear  
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Statistical analysis 
A paired t-test was used to analyse differences in continuous variables. Limits of agreement 
were assessed with Bland-Altman plots. Differences in paired proportions were determined 
with McNemar´s test. To analyse inter-rater agreement between the original report and re-
evaluation, categorical variables were analysed with Cohen´s Kappa coefficient (κ). Cohen´s 
kappa was also used for comparison between the decided and recommended preoperative 
treatment based on the tumour staging of the original report and re-evaluation. Agreement 
was determined as: no (κ = 0), slight (κ > 0 – 20), fair (κ = 0.21-0.40), moderate (κ = 0.41-
0.60), good (κ = 0.61-0.80) or excellent (κ = 0.81-1.00). 
 
Paper IV 
 
All patients undergoing surgery with a curative intent because of locally recurrent rectal 
cancer at Karolinska University Hospital between January 2003 and December 2013 were 
eligible for this study. Among these, all patients who had a pelvic MRI both before surgery 
for the primary tumour and the local recurrence were included. From the medical records 
information was retrieved concerning patient characteristics, pre- and postoperative treatment 
for the primary tumour, primary surgery, distant metastases before the local recurrence and 
surgery for the local recurrence. For outcome analyses, data obtained included 
histopathological reports and information regarding end of follow-up, death and distant and 
local re-recurrence after surgery for the local recurrence.  
Pelvic MR examinations were collected for the local recurrence, before any therapy for the 
primary tumour and if available also after preoperative treatment for the primary tumour. A 
MRI-specialised radiologist re-evaluated all MRI images and when judged necessary, another 
radiologist specialised in rectal cancer MRI performed a second re-assessment. The 
radiologists were blinded for the previous evaluation of the MRI for the local recurrence 
when re-evaluating the primary tumour MRI. The pre-treatment primary tumour MRI was re-
evaluated regarding tumour characteristics and nodal status and if a MRI after preoperative 
treatment was available, mrTRG and tumour volume was assessed. The location of the local 
recurrence at MRI was categorised according to the Memorial Sloan Kettering 
classification84. The primary tumours were classified using the same three-graded description 
as in study III (Table 9) and related to given preoperative treatment227. 
Measures of outcome included local re-recurrence, DFS, defined as the time from surgery for 
local recurrence to re-recurrence (local or systemic) or death from any cause and OS, defined 
as time from surgery for local recurrence to death from any cause. 
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Statistical analysis 
The Chi-square test was used to assess differences in proportions. Rates of OS, DFS and local 
re-recurrence were estimated with the Kaplan-Meier method and differences by means of the 
log rank test. Risk factors for non-radical surgery of the local recurrence and predictors of the 
localisation of the local recurrence were analysed with univariable logistic regression. 
Predictors of local re-recurrence, DFS and OS after surgery for local recurrence were 
determined in a univariable Cox regression analysis. Wald test was used to test for trends. 
 
Ethics 
The regional Ethical Review Board at Karolinska Institutet approved all studies. 
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RESULTS      
 
Paper I 
 
Among the 2619 patients included, 68.3 % (1789 patients) received preoperative (C)RT.  This 
proportion increased over time (p < 0.001) (Figure 5). The median age was 69 years (range 
27-100 years). 
 
 
 
 
 
 
 
 
 
Figure 5.  Proportion of rectal cancer patients receiving preoperative radiotherapy (RT) 
according to period of time 2000-2010 (p < 0.001). 
 
In Table 10 the correlation between clinical characteristics and preoperative treatment is 
shown. Omittance of preoperative RT or CRT was more common among elderly and in 
patients with comorbidity, especially in patients ≥ 80 years (adjusted OR 0.05; 95 % CI 0.04-
0.07) and with a CCI score ≥ 2 (adjusted OR 0.29; 95 % CI 0.21-0.39). Women were less 
likely to receive preoperative (C)RT in the unadjusted analysis (OR 0.84; 95 % CI 0.71-0.99) 
but the difference was not statistically significant in the multivariable model. The proportion 
of patients undergoing surgery at high volume centres increased over time (46.9 % 2007-2010 
vs. 37.2 % 2000-2002; p < 0.001). 
 
  
 56 
 
Table 10. Clinical characteristics in patients undergoing elective abdominal surgery for 
rectal cancer 2000-2010 and odds ratios for receiving preoperative (chemo-)radiotherapy 
((C)RT) from multivariable logistic regression analyses (n = 2619). 
  
  
  
Total (C)RT Multivariable logistic regression 
  
  
  
(n = 2619) (n = 1789) OR (95 % CI) p 
Age at operation 
  
   
 
< 0.001 
<65 
  
  
936 788 (84.2) 1.00  
65-79 
  
  
1208 889 (74.0) 0.56 (0.45-0.70)  
≥80 
  
  
475 112 (23.6) 0.05 (0.04-0.07)  
Sex 
  
  
   
 
0.28 
Male 
  
  
1562 1091 (69.8) 1.00  
Female 
  
  
1057 698 (66.0) 0.90 (0.74-1.09)  
CCI score    
 
< 0.001 
0 
  
  
2101 154 (73.5) 1.00  
1 
  
  
247 129 (52.2) 0.55 (0.40-0.76)  
≥2 
  
  
271 115 (42.4) 0.29 (0.21-0.39)  
Tumour height (cm)    
 
< 0.001 
0-5 
  
  
774 598 (77.2) 1.00  
6-10 
  
  
1022 715 (70.0) 0.56 (0.44-0.73)  
11-15 
  
  
817 474 (58.0) 0.27 (0.21-0.36)  
Hospital volume    
 
0.40 
<40 cases/year 
  
  
1456 946 (65.0) 1.00  
≥40 cases/year 
  
  
1163 843 (72.5) 1.09 (0.89-1.33)  
Year of surgery 
  
  
   
 
0.001 
2000-2002 
  
680 434 (63.8) 1.00  
2003-2006 
  
978 648 (66.2) 1.19 (0.94-1.52)  
2007-2010 
  
961 707 (73.6) 1.61 (1.25-2.07)  
 
In the subgroup analysis of the 2007-2010 cohort, 961 patients were identified. After 
exclusion of 107 patients who received treatment outside recommendations by guidelines or 
who had distant metastases, 854 patients remained for analysis. Of those 786 (92.0 %) 
patients discussed at a pretherapeutic MDT, 75.2 % (n = 591) were selected for preoperative 
(C)RT whereas this proportion was 44.1 % (n = 30) among those not discussed at a MDT. In 
total, 233 (27.3 %) patients were selected to no preoperative treatment, 499 (58.4 %) to 
preoperative short course RT and 122 (14.3 %) to preoperative CRT. In univariable logistic 
regression analyses a higher ASA score (III-IV) was strongly associated with less 
preoperative short course RT (OR 0.30; 95 % CI 0.19-0.50) and CRT (OR 0.19; 95 % CI 
0.09-0.38) while no statistically significant difference in preoperative treatment was seen in 
patients with a BMI over or under 25. In the multivariable model higher age, CCI score and 
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tumour level and less advanced cT and cN stage were correlated to less preoperative short 
course RT whereas only a less advanced cT and cN stage were statistically significantly 
associated with less preoperative CRT. There were no statistically significant differences 
between genders concerning preoperative RT or CRT compared to no preoperative treatment. 
Because of missing data regarding tumour level, cT and cN stage, only 734 of the 854 
patients could be categorised according to the three-tier tumour stage description. Table 11 
displays the distribution of those patients according to tumour stage and in relation to selected 
preoperative treatment. Of the 34 patients selected for no preoperative treatment despite 
intermediate or locally advanced tumours, 24 patients had a CCI score of ≥ 2 or were ≥ 80 
years. None of the remaining 10 patients had been diagnosed with pelvic malignancies the last 
13 years prior to the rectal cancer diagnosis, thus limiting the possibility of previous pelvic 
irradiation. Among the 33 patients with locally advanced tumours selected for preoperative 
short course RT, 28 (85 %) were > 65 years or had a CCI score ≥ 1. In the group of 318 
patients with early tumours the median age among the 175 (55 %) patients selected to 
preoperative (C)RT was 67 years compared to 76 years in the 143 (45 %) patients selected to 
no preoperative treatment (p < 0.001). In the early tumour stage group 180 patients had cT1-2 
tumours and of those 77 (43 %) were selected to preoperative treatment. 
 
Table 11. Preoperative treatment according to tumour stage in rectal cancer patients 
undergoing elective abdominal rectal cancer surgery 2007-2010 (n = 734). 
Tumour stage 
 
Preoperative treatment 
  No RT CRT 
Early 
  
143 (45.0) 170 (53.5) 5 (1.6) 
Intermediate 26 (8.4) 239 (77.1) 45 (14.5) 
Locally advanced 
  
8 (7.5) 33 (31.1) 65 (61.3) 
 
 
Paper II 
 
One patient who had surgery in 2011 and 300 patients with distant metastases by the time of 
surgery were excluded from the first study cohort of 2619 patients. Among the remaining 
2300 patients, 1617 (70.3 %) received preoperative (C)RT. The 3-year local recurrence, DFS 
and OS rates were 4.7 %, 68.6 % and 80.2 %, respectively and all outcome measures 
improved over time (p < 0.001) (Figure 6). 
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Figure 6. Rates (%) of local recurrence (LR), disease-free survival (DFS) and overall 
survival (OS in relation to time period for rectal cancer patients undergoing surgery 2000-
2010 (p < 0.001). 
 
In Figure 7 the Kaplan-Meier curve for DFS in relation to if preoperative (C)RT was 
delivered or not is displayed. In univariable Cox regression analyses preoperative (C)RT were 
associated with better DFS (OR 0.65; 95 % CI 0.57-0.73) and OS (OR 0.53; 95 % CI 0.47-
0.60).  
 
 
 
 
 
 
 
  
  
Figure 7 Kaplan-Meier analysis of disease-free survival according to delivered preoperative 
radiotherapy (RT) or no preoperative treatment. Log rank p < 0.001. 
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In multivariable Cox regression analyses, however, preoperative (C)RT did not significantly 
affect outcomes with regards to DFS and OS (Table 12). Advanced age, male sex, 
comorbidity, and a more advanced pTNM stage were predictors of inferior DFS and OS 
whereas a lower tumour level was associated with inferior OS only. Only low tumour level, 
more advanced pTNM stage (III) and time period were predictors of local recurrence but 
there was a trend towards lower local recurrence rates in patients who received preoperative 
(C)RT (OR 0.66; 95 % CI 0.41-1.05).  
 
 
Table 12. Multivariable regression analyses of clinical characteristics affecting local 
recurrence rate, disease-free survival (DFS) and overall survival (OS) in rectal cancer 
patients undergoing elective abdominal surgery 2000-2010 (n = 2300).  
 
  
 Adjusted HR (95 % CI) 
 
  
No. of patients 
(%) 
Local recurrencea 
DFSb OSc 
Preoperative (C)RT     
No 
  
683 (29.7) 1.00 1.00 1.00 
Yes 
  
1617 (70.3) 0.66 (0.41-1.05) 0.99 (0.85-1.15) 0.87 (0.74-1.01) 
Age at operation 
 
    
<65 
  
798 (34.5) 1.00 1.00 1.00 
65-79 
  
1069 (46.5) 0.89 (0.58-1.36) 1.37 (1.18-1.60) 1.68 (1.43-1.97) 
≥80 
  
433 (18.8) 1.25 (0.69-2.27) 2.60 (2.14-3.17) 3.52 (2.87-4.32) 
Sex 
  
    
M 
  
1364 (59.3) 1.00 1.00 1.00 
F 
  
936 (40.7) 0.80 (0.56-1.16) 0.82 (0.73-0.93) 0.79 (0.69-0.89) 
CCI score     
0 
  
1852 (80.5)  1.00 1.00 
1 
  
214 (9.3)  1.58 (1.32-1.89) 1.55 (1.29-1.87) 
≥2 
  
234 (10.2)  1.83 (1.53-2.18) 2.02 (1.69-2.42) 
Tumour heightd     
0-5 
  
697 (30.4) 1.00  1.00 
6-10 
  
893 (38.9) 0.46 (0.31-0.70)  0.77 (0.67-0.90) 
11-15 
  
705 (30.7) 0.42 (0.26-0.66)  0.77 (0.65-0.90) 
pTNM staged     
I-II 
  
1404 (62.2) 1.00 1.00 1.00 
III 
  
852 (37.8) 2.41 (1.66-3.50) 2.09 (1.85-2.36) 2.00 (1.76-2.26) 
a Adjusted for preoperative (C)RT, age, sex, tumour height, time period, pTNM stage, adjuvant chemotherapy 
b Adjusted for preoperative (C)RT, age, sex, comorbidity, time period, pTNM stage and adjuvant chemotherapy 
c Adjusted for preoperative (C)RT, age, sex, comorbidity, tumour height, time period and pTNM stage 
d Data missing on pTNM stage (n = 44) and tumour height (n = 5) 
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In a separate multivariable Cox regression analysis of OS, patients were stratified for age and 
CCI score (Table 13). Irradiated patients with a CCI score ≥ 1 had statistically significantly 
better OS following compared to non-irradiated patients (OR 0.65; 95 % CI 0.49-0.87). 
Preoperative (C)RT did not significantly improve OS in patients ≥ 80 years. However, in 
younger patients preoperative (C)RT was correlated to better OS (OR 0.74; 95 % CI 0.61-
0.89).  
 
Table 13. Stratified multivariable Cox regression analyses regarding overall survival in 
relation to preoperative treatment in patients undergoing rectal cancer surgery 2000-2010. 
   Multivariable Cox regression 
 
  
 HR (95 % CI) P 
Agea 
    
< 80 
   
0.001 
No preoperative RT 1.00 
 
Preoperative RT 0.74 (0.61-0.89) 
 
≥ 80 
   
0.566 
No preoperative RT 1.00 
 
Preoperative RT 1.08 (0.82-1.42) 
 
 
    
Charlson Comorbidity Indexb 
  
0 
   
0.828 
No preoperative RT 1.00 
 
Preoperative RT 0.98 (0.81-1.19) 
 
≥ 1 
   
0.003 
No preoperative RT 1.00 
 
Preoperative RT 0.65 (0.49-0.87) 
 
 
 
Paper III 
 
Of 100 consecutive patients eligible, pretherapeutic MR images were available in 94. In 86 % 
among the remaining patients, the MRI examinations were considered to have met predefined 
accepted standards. In the original reports the proportion of missing data were 34 % for T 
stage, 34 % for EMVI stage, and 10 % for MRF involvement. For patients with visible 
tumours according to the re-evaluation (n = 90) the proportion of missing data regarding the 
extent of extramural growth was 50 %. Absent data for N stage and lateral lymph node 
metastasis was considered as negative findings. The agreement amongst the original MRI 
report and the re-evaluation was good for T stage category (κ = 0.71), moderate for N stage 
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category (κ = 0.42) and excellent for EMVI status (κ = 0.86) and MRF involvement (κ = 
0.88). 
When categorising the tumours into early, intermediate and locally advanced according to 
Table 9, 28 of the original reports were missing data, making this tumour stage grouping 
impossible. In the 66 patients possible to analyse, the agreement between original reports and 
re-evaluation was moderate (κ = 0.46) and only 42 (64 %) of those patients were categorised 
into the same tumour stage group in the re-evaluation and the original reports (Table 14). 
 
Table 14. Agreement between tumour stage based on the original MRI reports and the re-
evaluation (κ = 0.46), n (%).  
 
 
 
 
 
 
Of all 94 patients, two had atypical preoperative treatment and were excluded from further 
analysis. Among the remaining 92 patients, 20 patients were selected to no preoperative 
treatment, 57 to preoperative short course RT and 15 to CRT. The agreement between 
recommended preoperative treatment according to the re-evaluation and the treatment decided 
on was fair (κ = 0.33) (Table 15). The proportion of patients receiving overtreatment was 18 
% and undertreatment 24 %, according to this comparison. The agreement between 
recommended preoperative treatment according to the original report and received 
preoperative treatment was slight (κ = 0.12). 
 
Table 15. Agreement between recommended preoperative treatment according to the re-
evaluation of MR-investigations and selected preoperative treatment (κ = 0.33), n (%).  
Preoperative 
treatment 
recommended 
Preoperative treatment selected 
No RT CRT 
No 11 (44) 13 (52) 1 (4) 
RT 5 (12) 31 (80) 3 (8) 
CRT 4 (14) 13 (46) 11 (39) 
Tumour stage 
(re-evaluation) 
Tumour stage 
(original report) 
 Early Intermediate Locally advanced 
Early 9 (69) 3 (23) 1 (8) 
Intermediate 12 (43) 14 (50) 2 (7) 
Locally 
advanced 
2 (8) 4 (16) 19 (76) 
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Paper IV 
 
A total of 76 patients underwent surgery with a curative intent because of locally recurrent 
rectal cancer during the study period. After exclusion of 20 patients in whom MRI before 
primary surgery was unavailable and two patients in whom surgery was indicated by a re-
recurrence, 54 patients remained for analyses. The median age at the time of surgery of the 
local recurrence was 65 years (range 42-82 years). Forty-two (78 %) patients received 
preoperative (C)RT prior to primary surgery and of those, 20 patients underwent a second 
MRI after preoperative treatment. Of the primary tumours, 10 (19 %) were categorised as 
early, 13 (25 %) as intermediate and 30 (57 %) as locally advanced according to the MRI re-
evaluation. One patient had a primary tumour that was not possible to detect on MRI. 
Preoperative CRT was only given to 10 out of the 30 patients with locally advanced tumours 
and in total 24 (45 %) were undertreated regarding preoperative (C)RT for the primary 
tumours according to the Swedish national guidelines for colorectal cancer. 
Some 13 (24 %) of the patients had suspected lateral lymph node metastases on MRI before 
primary surgery. On the MRI of the local recurrence, the lateral compartment of the pelvis 
was involved in 31 (57 %) of the patients. In a univariable logistic regression analysis, a right-
sided involved lateral lymph node was associated with an ipsilateral local recurrence (OR 
5.50; 95 % CI 1-18-25.53). This relationship could not be demonstrated on the left side. Nor 
could a statistically significant association be shown between involved lateral lymph nodes 
per se and a laterally located local recurrence (OR 3.17; 95 % CI 0.76-13.20). 
In 35 (65 %) of the patients a R0 resection of the local recurrence was accomplished. None of 
the primary tumour MRI characteristics predicted for a R0 resection of the local recurrence in 
an unadjusted logistic regression analysis. However, in those 20 patients in whom tumour 
regression was assessed with a second MRI following preoperative treatment, a tumour 
volume decrease of ≤ 70 % was correlated to fewer R0 resections (OR 0.07; 95 % CI 0.01-
0.84). A TRG of 4-5 was also associated with a lower rate of R0 resection, although without 
statistical significance (OR 0.14; 95 % CI 0.02-1.14). 
The 3-year local re-recurrence rate, DFS and OS after surgery for local recurrence were 41 %, 
26 % and 57 %, respectively. In a univariable Cox regression analysis a lateral recurrence 
predicted for an inferior outcome in terms of OS (HR 3.03; 95 % CI 1.50-6.12) and DFS (HR 
2.23; 95 % CI 1.19-4.18). However, none of the primary tumour MRI characteristics were 
statically significantly associated with worse outcomes. 
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DISCUSSION     
 
Survival and local recurrence rates in rectal cancer patients have improved rapidly during the 
past decades due to advances in surgery and the introduction of preoperative (C)RT. Also, 
some of the patients with recurrent or metastatic disease in whom palliative treatment 
previously remained as the only alternative can now be treated with a potential for cure. 
Although improvements have been made with minimally invasive surgical techniques, nerve-
sparing surgery, enhanced perioperative management and refined radiation technique, rectal 
cancer treatment is still associated with substantial morbidity. Preoperative treatment 
selection in the rectal cancer MDTs is often complex and optimal decision-making requires 
reliable information regarding both tumour growth and patient characteristics. This thesis 
aimed to investigate some of the aspects influencing treatment decision in rectal cancer 
management. 
The findings from several trials of halved local recurrence rates following preoperative short 
course RT irrespective of quality of surgery performed, have largely impacted rectal cancer 
treatment in Sweden181, 186, 188. Indeed, in paper I the proportion of irradiated patients 
increased from 2000 to 2010 and in the most recent time period (2007-2010) this proportion 
was 74 %. The vast majority of those patients were selected for short course RT. Whether as 
much as three fourths of rectal cancer patients undergoing abdominal surgery is best served 
by preoperative (C)RT could be discussed. In the trials showing a benefit of preoperative RT, 
the gains were mainly evident in stage II-III disease where the risk of local recurrence is 
greater than in stage I rectal cancer180, 186. In the subgroup analysis of the 2007-2010 patients 
in paper I, 55 % of patients with early cancers and 43 % with T1/2N0 tumours were decided 
for preoperative (C)RT. Interestingly, patients in the early group selected for preoperative 
(C)RT were significantly younger than patients selected for immediate surgery. It could be 
speculated that some patients in this group were inadequately selected for more aggressive 
treatment because of young age. Although limited by the absence of information regarding 
predictive factors influencing preoperative treatment decisions such as MRF involvement, 
EMVI status, presence of involved lateral lymph nodes and T 3/4 substage, the results of this 
paper indicated overuse of preoperative (C)RT. It is important to keep the negative effects of 
(C)RT in mind when choosing treatment strategies for rectal cancer patients173, 190, 217. 
Although to a lesser extent, some of the papers in this thesis also indicated undertreatment 
among certain patient categories. In the 2007-2010 subgroup analysis of paper I, 34 (8 %) of 
the 416 patients with intermediate or locally advanced tumours did not receive any 
preoperative treatment. In 10 of these patients neither age, nor comorbidity nor previous 
pelvic irradiation could explain this finding. Furthermore, in paper III the recommended 
preoperative treatment according to the original reports and the selected preoperative 
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treatment was only slight (κ = 0.12). Also, of the 54 patients included in paper IV, only 10 of 
the 30 patients received preoperative CRT despite locally advanced primary tumours and in 
total, 45 % of the patients obtained less intense preoperative treatment than indicated by the 
Swedish national guidelines for colorectal cancer. The patients in this study were relatively 
young and likely not burdened by comorbidity since they subsequently underwent surgery for 
the local recurrence. Hence, advanced age or comorbidity does not explain the large 
proportion of patients that did not receive preoperative (C)RT. In this group of patients it 
cannot be ruled out that at least some of the local recurrences could have been avoided, had 
optimal pre-therapeutic decisions been made prior to surgery for the primary tumour. 
In a report from the Dutch Surgical Colorectal Audit, 88 % of the rectal cancer patients 
received preoperative (C)RT according to the recommendations in the Dutch guidelines and 
in 66 % of the patients with T1N0 tumours preoperative RT was delivered despite not 
indicated237. Several other population-based investigations have reported suboptimal 
guidelines adherence and also inferior outcomes in rectal cancer patients in whom compliance 
to guidelines was inadequate239, 254, 255. Age and comorbidity are known risk factors for 
guidelines violation and omittance of preoperative (C)RT in rectal cancer management232, 237, 
239, 254. In paper I, both age and comorbidity were strong predictors of delivery of preoperative 
RT. Among patients with a CCI score of ≥ 2 or age ≥ 80 years only 42 % and 24 %, 
respectively, received preoperative (C)RT whereas the proportion receiving (C)RT in the 
population was 68 %. To abstain from preoperative (C)RT may be correct in the management 
of the patients with severe comorbidity or advanced age considering the acute toxic effect and 
life expectancy in this group of patients241, 244, 256. However, in this study the proportion of 
patients receiving preoperative treatment was significantly lower also among the patient 
between 65 – 79 years or with mild comorbidity (CCI score = 1). Although chemoradiation 
may not be feasible in frail patients, it has not been proven that short course radiation in these 
patients correlates to more acute toxic effects compared to in younger patients without 
comorbidity235, 244, 245. Publications from the Stockholm III trial have shown that 5 x 5 Gy 
with a delay of 4-8 weeks before surgery compared to 5 x 5 Gy and immediate surgery, 
increases the rate of pCR, decreases the rate of postoperative complications and has similar 
rates of local recurrence199, 200. In patients with locally advanced tumours who are not fit for 
preoperative CRT, short course RT with delayed surgery may thus be considered198. 
Preoperative RT has been shown to increase local control in rectal cancer patients > 75 
years242. The 3-year local recurrence rate in paper II was 4,7 %, which is consistent with a 
previous report from the SCRCR257. Despite a relatively large study cohort, the low number 
of local recurrences made statistical analyses regarding the impact of preoperative (C)RT in 
relation to age and comorbidity unfeasible. The OS and DFS for patients more than 65 years 
and patients with a CCI score of ≥ 1 were significantly lower. However, stratified analyses 
demonstrated a benefit of preoperative RT in patients with comorbidity (CCI score ≥ 1) 
regarding OS (adjusted HR 0.65; 95 % CI 0.49-0.87) while preoperative RT in patients ≥ 80 
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years did not significantly influence OS rates. Efficient treatment selection ultimately 
decreases differences in long-term outcomes between patients. That is, patients with more 
advanced tumours should receive more intense preoperative treatment and optimally this will 
improve local control and possibly also long-term survival. Hence, the results could be 
interpreted so that management regarding preoperative treatment selection in the elderly was 
adequate. The patients ≥ 80 years who actually received RT possibly had more advanced 
tumours. On the other hand, patients with comorbidity received preoperative RT to a lesser 
extent and this may reflect inadequate preoperative treatment selection. 
Since TME surgery was introduced and fully adopted, the effect of preoperative RT on local 
control has not been translated into improved survival outcomes other than for subgroups of 
patients188. Long-term results from the Dutch TME trial showed a better 10-year OS in 
patients with stage III tumour with a negative CRM after preoperative 5 x 5 Gy followed by 
surgery compared to surgery alone (50 % vs. 40 %; p = 0.032)180. Paper I showed an 
increased use of (C)RT throughout the study period and within the same study cohort, only 
excluding stage IV patients, the rates of local recurrence, DFS and OS improved concurrently. 
There are several factors possibly contributing to the improvements in long-term outcomes. 
Improved treatment selection due to enhancements in clinical tumour staging with MRI, the 
introduction of MDT conferences, optimised TME surgery and enhanced perioperative care 
may explain better outcomes. However, it cannot be ruled out that the increased usage of 
preoperative (C)RT contributed to improved survival, at least in subgroups of patients. 
Indeed, the adjusted analysis showed a tendency of better OS following preoperative (C)RT 
(OR 0.87; 95 % CI 0.74-1.01). On the other hand, all patients included in paper I and II 
underwent abdominal surgery. According to a report from the SCRCR including all rectal 
cancer patients in Sweden, the proportion of non-resected patients increased from 17.5 % in 
2001-2006 to 25.8 % in 2007-2010 (p < 0.001)257. A different selection to surgery could 
possibly influence the outcomes among patients included in paper I and II.  
It has previously been reported that the proportion of patients receiving preoperative RT for 
rectal cancer is lower among women than in men258, 259. A recently published study also 
showed that incomplete dosage of preoperative RT was more common in women whereas age 
and comorbidity did not predict treatment completion260. Contrary to the findings above, 
adjusted analysis in paper I could not display any gender inequalities regarding delivery of RT 
(OR 0.90; 95 % CI 0.74-1.09), although completion of irradiation could not be controlled for. 
In paper II however, male sex predicted for worse OS and DFS, even when age and 
comorbidity were adjusted for. The pelvic anatomy differs between genders with regards to 
both organ content (uterus, ovaries, prostate, vesicles) and the width of the pelvic cavity. 
Therefore, surgery of the narrower male pelvis is considered to be more arduous, especially in 
patients with low tumours. A higher proportion of preoperative irradiation for low tumours 
among men than women may be justified in order to accomplish tumour regression, enhance 
quality of TME, reduce CRM involvement and thereby improve oncological outcomes.  
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A prerequisite for optimised treatment selection at the pretherapeutic MDT conferences is 
adequate information regarding tumour growth. MRI is the standard tool for assessment of T 
stage in rectal cancer but several other predictors of resectability, local and systemic 
recurrence can also readily be assessed with MRI. In the Stockholm-Gotland area of Sweden 
repeated educational efforts have been made to improve the performance and reporting of 
MRI in rectal cancer. In paper III the compliance to predefined standards of MRI examination 
was 86 %. The information analysed in this study was based on MRI investigations 
performed in 2010. Although this was relatively recently, the rapid increase in knowledge 
regarding the importance of the information from pretherapeutic MRI possibly has improved 
the performance regarding MRI for rectal cancer since then. 
In a study by Al-Sukhni et al., 128 pretherapeutic narrative MRI reports were revaluated. Not 
even 40 % of these reports were complete with regards to cT stage, cN stage and MRF 
(CRM) involvement261. Aiming at standardised scanning technique and systemised reporting 
in rectal cancer MRI, the MERCURY study group developed a proforma-based tool262. To 
increase completeness of pretherapeutic tumour staging and aid treatment-decisions at the 
MDTs, an adaption of this protocol was introduced in Sweden in 2014. Thus, the somewhat 
discouraging results in paper III regarding completeness of reporting of important tumour 
characteristics such as T stage and EMVI could partly be explained by the absence of a 
structured reporting system during the study period. Also, although the accuracy and 
importance of pretherapeutic T staging with MRI was known in 2010, the prognostic 
significance of mrEMVI was not fully embraced72, 73. 
Ninety % of the original reports reported regarding MRF involvement and the agreement 
between the original reports and the re-evaluation was excellent (κ = 0.88) for this factor. It 
appears as if the knowledge concerning the predictive value of an involved MRF has had a 
large impact on rectal cancer MRI reading70. However, sufficient quality in the assessment of 
T is not yet maintained concerning the relatively low level of agreement between the original 
reports and re-evaluation, and also the large proportion of missing data for T stage and extent 
of extramural growth. The assessment of nodal status on MRI is flawed by relatively low 
sensitivity and specificity57. Although this in part could explain the poor agreement for N 
stage, a better congruence was expected. Further education and radiological workshops is 
warranted in order to improve MRI interpretation and reporting. 
MRI staging of good quality can make treatment strategies more adequate and improve 
outcomes with respect to number of complete resections, rates of local recurrence and 
survival263. In paper III, the inadequacies in the original reports translated into only moderate 
agreement between original reports and the re-evaluation when tumours were staged into 
early, intermediate and locally advanced. The fact that only 66 patients could be stage 
grouped in this analysis because of missing data in the original reports decreases the 
reliability of the agreement measurement but of the classifiable patients, 24 (66 %) were 
inadequately categorised. Moreover, the poor agreement (κ = 0.12) between treatment 
 67 
 
recommended according to the original reports and the treatment actually received, raises 
concern. Inadequate MRI staging may have caused unnecessary morbidity because of 
overtreatment as well as inferior outcomes among undertreated patients. When comparing the 
delivered with the suggested treatment from the re-evaluation, the agreement was better (κ = 
0.33), though far from satisfactory. Preoperative treatment selection is not guided solely by 
MRI staging. Frailty could be a reasonable cause to abandon guideline recommendations 
resulting in undertreatment for some patients. To explain the overtreatment displayed in paper 
III is more difficult. Optimised MRI staging is of vital importance to ensure proper decision-
making. 
Evaluation of MRI interpretation quality would optimally include correlation to postoperative 
histopathology as the reference standard. However, the tumour properties of the resected 
specimen are affected by preoperative treatment. Since no other radiological modality more 
accurately can assess local tumour growth in rectal cancer, re-evaluation by experts in rectal 
cancer MRI reading remains as the best available alternative. 
To explore predictive factors for outcome in patients undergoing treatment for locally 
recurrent rectal cancer is difficult. With TME surgery and preoperative (C)RT, local 
recurrence rates of about 5 % have been shown and among the patients with local recurrences 
the majority receive palliative treatment only, because of disseminated disease or unresectable 
tumours180, 192, 264. Thus, few patients with locally recurrent rectal cancer are considered for 
surgery and the study cohorts available are small. Furthermore, the selection criteria regarding 
resectability differ among centres managing locally recurrent rectal cancers, which make 
comparison of studies reporting outcome difficult. Also, no uniform classification of local 
recurrence exists and the heterogeneity among these tumours requires individualised 
treatment-decisions. Paper IV primarily aimed to investigate whether there are tumour 
characteristics at the primary tumour MRI predictive for long-term outcome after surgery for 
local recurrence but no such association could be revealed. Naturally, many factors after the 
staging of the primary tumour could influence the results after surgery for the local 
recurrence. Patient characteristics such as age and comorbidity, adjuvant treatment and 
quality of surgery of the primary tumour and the local recurrence, distant metastases before 
local recurrence and the biological properties of the tumours may explain differences in 
outcome. Due to a small study population these factors were not possible to control for in the 
statistical analyses. The small study population itself implies that although statistical 
significance was not obtained it cannot be excluded that some of the factors analysed can 
show predictive values in a larger setting. The evidence regarding management of locally 
recurrent rectal cancer is generally based on retrospective data from single-centre cohort 
studies. To further increase knowledge in this field, an international register with 
prospectively registered data and multicentre investigations is warranted. 
A R0 resection is a prerequisite to improve long-term outcome in locally recurrent rectal 
cancer159. In the series of patients in paper IV, 65 % underwent a R0 resection, which is in 
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line with previous reports156, 157, 159. There was an association between response to 
preoperative (C)RT for the primary tumour and the rate of radical resection of the recurrence. 
Possibly, there are features regarding tumour biology that predict for both response to 
preoperative treatment and the ability to achieve successful treatment of the local recurrence 
and that this information could be used in the treatment selection for the local recurrence. 
Two recent reviews have evaluated re-irradiation in patients with locally recurrent rectal 
cancer265, 266. It was concluded that despite the absence of randomised trial and the 
heterogeneous treatment regimens regarding both (C)RT and surgery in the included 
investigations, re-irradiation can be recommended for selected patients with acceptable safety 
and favourable outcomes regarding R0 resection rate. The information on primary tumour 
response to (C)RT may be useful in this selection. 
In a study by Syk et al. no correlation could be detected between lateral lymph node 
involvement on primary tumour MRI and later local recurrence. This report was based on 
only 33 patients and more than 40 % of the primary tumours were located in the upper 
rectum267. On the contrary, other investigations have reported on an association between 
enlarged lateral lymph nodes (≥ 5 mm) and a lateral local recurrence67, 268. Fujita et al. showed 
that among patients randomised to only TME surgery the rates of lateral and overall local 
recurrence were higher than in patients that also underwent LLND137. However, in this trial 
none of the patients received preoperative (C)RT. In paper IV a lateral lymph node on 
primary tumour MRI was significantly associated with an ipsilateral local recurrence but only 
on the right side. As only 13 out of 54 patients had suspected lateral lymph nodes in this study 
it is difficult to draw any firm conclusion from this finding. Several authors have used size as 
a predictor for lateral lymph node involvement and different cut offs such as 5, 8 and 10 mm 
have been suggested67, 137, 269. In paper IV only morphological criteria (irregular border, 
presence of mixed signal intensity) were used, based on experience from the MERCURY 
study group68. The optimal criteria for lateral lymph node metastasis remain to be defined 
with regards to sensitivity and specificity. Also, the downstaging effect on lymph nodes 
following preoperative (C)RT constitutes a major problem when histopathogical evaluation of 
pretherapeutic MRI is undertaken. 
All investigations in this thesis have been made using observational data. Retrospective 
observational cohort studies have their main advantages in the ability to use existing data and 
in a short time analyse the exposure and outcome of many patients over a long period of time. 
However, these studies are associated with a risk of bias and confounding influencing the 
outcome and thereby affecting the internal validity. The data in the SCRCR are prospectively 
registered with almost complete coverage and reported with very good validity. Therefore, the 
risk of selection bias or information bias is limited and to decrease the risk of confounding, 
multivariable analyses were used in paper I-II. The reporting to Swedish National Patient 
Register is mandatory regarding inpatient care and coverage is good, but even though 
evaluation of this register has shown a rather good validity there is a risk of misclassification 
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bias because of inadequacies in the diagnosing of disease. Also, since the coverage of 
outpatient data in the Swedish National Patient Register is lacking in completeness only data 
on inpatient care was used and therefore there could be patients included in paper I-II with 
significant comorbidity not recorded in the CCI classification. Although the CCI based on 
diagnosis is merely an approximation of physical function, correlation to ASA score, that 
possibly reflects physical function better, was good. The external validity of the results of 
paper I-III in the thesis is concluded to be good since the data used is population-based. The 
small number of patients with local recurrences made other study design than the 
retrospective observational used in paper IV, difficult. 
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CONCLUSIONS     
 
Overall conclusion 
 
There is room for improvements regarding MRI performance and interpretation, and also 
regarding the selection to preoperative therapy in rectal cancer patients, especially among 
patients with comorbidity.  
 
Specific conclusions 
 
The use of preoperative treatment increased over time. Advanced age and comorbidity were 
strong predictors for omittance of preoperative treatment and even patients with only mild 
comorbidity and in the beginning of aging received substantially less (C)RT. Signs of 
overtreatment and to a lesser extent also undertreatment were revealed. 
Local recurrence rates, DFS and OS improved over time. Age and comorbidity predicted for 
worse survival outcomes. An improvement in OS following preoperative treatment was seen 
in patients with comorbidity but not among the elderly. 
Compliance to MRI protocol standards was incomplete. Missing data and inadequacies in 
original MRI reports made complete preoperative tumour staging impossible, leading to a risk 
of impaired treatment selection. 
A significant number of patients with operated local recurrences received less preoperative 
treatment for the primary tumour than recommended by guidelines. A tumour volume 
shrinkage on MRI after preoperative (C)RT for primary rectal cancer predicted for a higher 
rate of R0 resection of the local recurrence. However, no associations between MRI 
characteristics of the primary tumour and long-term outcomes after surgery for locally 
recurrent rectal cancer were found.  
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FUTURE PERSPECTIVES   
 
Notwithstanding the successful development regarding local recurrences and survival 
outcomes up until now, there are many areas that warrant further improvements in rectal 
cancer management. Systemic disease remains to be a problem, adverse effects of surgical 
and oncological treatment still are considerable and the proportion of rectal cancer patients in 
whom curative treatment is judged unfeasible, is not negligible. With more therapeutic 
options available and an increasing life expectancy, treatment selection is becoming more 
complex and the need for a multidisciplinary approach even more important. Objective 
measure of physical function and evidence on how to best treat frail patients is needed for an 
individualised treatment-decision. 
Detection of rectal tumours at an earlier stage allows for a less aggressive treatment strategy 
and may improve outcomes. Faecal blood tests used in screening programmes are highly 
specific while sensitivity is more unsatisfactory. Endoscopy on the other hand, is resource 
demanding and non-adherence remains a challenge. Circulating tumour cells or fragments of 
tumour DNA in the blood can possibly be of importance in the future as a less invasive 
screening alternative. Potentially these liquid biopsies also can evaluate treatment effect, 
identify high-risk tumours and be used to detect recurrence.  
Adequate tumour response assessment after preoperative treatment is increasingly important 
in an era of rising interest in organ preservation. MRI has shown promise in the assessment of 
complete response but there are further improvements to be made regarding certain imaging 
features such as nodal involvement. Numerous regimens of organ preservation programs have 
been proposed with various preoperative treatments, indications for patient inclusion 
depending on tumour properties, the use of TEM and surveillance. More evidence is 
warranted before organ preservation can be generally recommended for certain patients. 
Optional radiation techniques beside conventional external RT have emerged. With contact 
brachytherapy, Intensity-Modulated RT (IMRT) or proton therapy, radiation can be delivered 
more precisely to the tumour thereby minimising damage to normal, adjacent tissue. 
However, the clinical benefit with regards to toxicity, late adverse effects and oncological 
outcomes needs to be further investigated. Laparoscopy has shown short-term benefits in 
rectal cancer surgery. For more recently introduced minimal invasive techniques such as 
robotic surgery and ta-TME the evidence is still limited and more knowledge is needed. This 
applies for both the long-term benefits of these techniques regarding oncologic outcome and 
late adverse effects. Re-irradiation of locally recurrent rectal cancer appears to be feasible but 
optimal dose and fractionation remains to be elucidated. To increase knowledge concerning 
multimodal treatment of local recurrences, international cooperation with prospective 
registration of data and multicentre investigations are required.   
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SAMMANFATTNING PÅ SVENSKA  
 
Kolorektalcancer (cancer i tjock- och ändtarm) är den tredje vanligaste cancerformen i 
världen och fler insjuknar i västvärlden än i Afrika och Asien. Hos en tredjedel av patienter 
med kolorektalcancer är tumören belägen i rektum. Varje år diagnosticeras 2000 svenskar 
med rektalcancer och förutom hög ålder och manligt kön har man sett att rött kött, lågt intag 
av fibrer, alkohol, rökning, övervikt och inflammatorisk tarmsjukdom ökar risken. Ärftlighet 
ses hos en femtedel av alla insjuknade. Vanliga symptom vid rektala tumörer är trötthet på 
grund av anemi (blodbrist), rektal blödning, förändrade avföringsvanor och ändtarmssmärtor.  
Den botande behandlingen består av kirurgi där man tar bort rektum. Historiskt har 
rektalcancerkirurgi varit förknippat med dålig överlevnad, hög risk för lokalt återfall och 
mycket komplikationer. Förnyad operationsteknik (TME), där också hela det fettskikt som 
omgärdar rektum tas bort, har förbättrat prognosen avsevärt. Den relativa 5-årsöverlevnaden 
är idag närmare 70 % i Sverige. Trots förbättrad teknik är långtidsbiverkningar av kirurgin, 
som påverkan på sexualfunktion och urin- och avföringsinkontinens vanligt. Operationerna 
kan göras öppet eller med titthålsteknik. I en mindre andel av patienterna med tidiga tumörer 
kan tumören tas bort lokalt och rektum kvarlämnas. 
Strålbehandling (RT) kan ta död på mikroskopiska canceransamlingar i anslutning till 
tumören, exempelvis i lymfkörtlar, och åstadkomma tumörkrympning vilket ökar chansen att 
åstadkomma radikal kirurgi. Vid avancerade tumörer kombineras preoperativ RT med 
cellgiftsbehandling (CRT). Preoperativ (C)RT i kombination med TME har minskat risken för 
ett lokalt återfall till ca 5 %. Dock finns komplikationer också till RT. Övergående påverkan 
med diarréer, illamående, trötthet, infektioner och hudproblem är vanliga. På lång sikt 
förefaller komplikationer associerade med rektalcancerkirurgin vara ännu vanligare hos 
patienter som också fått RT. 
Patienter med konstaterad tumör i ändtarmen genomgår rektoskopi för att kartlägga 
tumörnivån och vävnadsprov tas för att bekräfta diagnosen. En datortomografi av buk och 
bröstkorg utförs för att utesluta fjärrmetastaser. För att bedöma tumörens lokala växtsätt görs 
en magnetresonanstomografi (MRT). Ett flertal faktorer på MRT kan förutsäga risken för 
tumöråterfall och chansen att åstadkomma radikal kirurgi. Riktlinjer för val av 
behandlingsregim baseras på MRT, där tumörerna kan indelas i tidiga, intermediära och lokalt 
avancerade och dessa olika tumörstadier rekommenderas direkt kirurgi, preoperativ RT 
respektive preoperativ CRT. Beslut om preoperativ behandling och kirurgi tas vid 
multidisciplinära teamkonferenser (MDT-konferenser) där både tumör- och patientfaktorer 
påverkar behandlingsvalen. 
Hög ålder och komorbiditet (samsjuklighet) utesluter ofta patienter från deltagande i kliniska 
studier. Därför är dessa patientgrupper dåligt studerade och rekommendationer för hur de bäst 
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ska behandlas saknas. Denna avhandling undersökte hur patientfaktorer samt tumörfaktorer 
utifrån MRT-undersökningar påverkar de preoperativa behandlingsvalen vid rektalcancer. 
I delarbete I studerades hur ålder och komorbiditet påverkade val till preoperativ RT. Data 
för samtliga 2619 patienter som opererades för rektalcancer i Stockholm-Gotland 2000-2010 
inhämtades från det svenska kolorektalcancerregistret. Uppgifter om komorbiditet inhämtades 
från Socialstyrelsens patientregister. 68 % av alla patienter fick (C)RT innan operation och 
användningen ökade över tid. Bland patienter med komorbiditet erhöll endast 47 % 
preoperativ (C)RT och motsvarande andel bland äldre patienter var 24 %. En relativt stor 
andel av patienter med tidiga tumörer fick RT och en liten andel av patienter med mer 
avancerade tumörer fick ingen preoperativ behandling alls. 
Delarbete II syftade till att utreda hur val av preoperativ behandlingsstrategi hos äldre och 
sjuka påverkade långtidsprognosen. För denna studie användes uppgifter på 2300 patienter 
från patientgruppen i delarbete 1 utan tecken till fjärrmetastaser vid operation. Preoperativ 
(C)RT påverkade inte överlevnad eller återfallsfrekvens totalt eller bland de äldre men hos 
patienter med komorbiditet sågs en bättre överlevnad efter preoperativ (C)RT. 
Delarbete III studerade standarden på utförande, tolkning och rapportering av MRT vid 
rektalcancer och i vilken mån detta påverkar behandlingsval. MR-undersökningar på 94 
patienter som opererades 2010 från studiegruppen i delarbete I inhämtades. MR-
undersökningarna utvärderades och jämfördes med ursprungsutlåtandet. Följsamheten till 
riktlinjer för MRT-utförande var ofullständig. På grund av bristfällig information i 
originalutlåtandet kunde tumörstadieindelning endast göras i 70 % av patienterna och 
överensstämmelsen mellan originalutlåtanden och eftergranskningen var inte 
tillfredsställande. Detta föreföll påverka val av preoperativ behandlingsstrategi. 
I delarbete IV undersöktes om faktorer vid MR-undersökning för primär rektalcancer kan 
användas för att förutsäga prognosen efter operation av lokalt tumöråterfall. Behandlingsvalen 
vid primärtumören studerades också. 54 patienter som opererats för ett lokalt återfall av 
rektalcancer på Karolinska Universitetssjukhuset 2003-2013 och som hade genomgått MRT 
för primärtumören inkluderades. MR-undersökningarna eftergranskades och ur 
patientjournalerna inhämtades uppgifter om uppföljning. Vid analysen hittades inga faktorer 
på den första MR-undersökningen som ökade risken för död eller ett nytt återfall efter 
operationen för det lokala återfallet. Däremot korrelerade en bra respons på preoperativ 
(C)RT för primärtumören till en större andel radikalt opererade lokala recidiv. Även i denna 
studie fanns tecken till underbehandling avseende preoperativ (C)RT av primärtumören. 
Sammanfattningsvis kunde denna avhandling visa att den information som används och de 
beslut som tas vid MDT-konferenser kan förbättras avseende val till preoperativ behandling 
och att detta kan påverka långtidsprognosen vid rektalcancer.  
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